[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 105
1. Reddy KA, Trimurthy Rao A, Krishna R, Manjula Y, Sambasiva Rao M, Srinivasulu K: A rare case of bilateral basal cell adenomas in the parotid glands. Indian J Surg; 2008 Feb;70(1):32-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of bilateral basal cell adenomas in the parotid glands.
  • Based on clinical features a provisional diagnosis of bilateral pleomorphic adenomas was made.
  • Bilateral superficial conservative parotidectomy with facial nerve preservation revealed bilateral encapsulated and lobulated tumors which on histopathological examination revealed bilateral basal cell adenomas in both parotid glands.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 2000 Jan;114(1):83-5 [10789423.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2000 Sep-Oct;62(5):278-81 [10965265.001]
  • (PMID = 23133013.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3452595
  • [Keywords] NOTNLM ; Basal cell adenoma / Bilateral parotid tumors / Parotid tumors
  •  go-up   go-down


2. Minicucci EM, de Campos EB, Weber SA, Domingues MA, Ribeiro DA: Basal cell adenoma of the upper lip from minor salivary gland origin. Eur J Dent; 2008 Jul;2(3):213-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the upper lip from minor salivary gland origin.
  • Basal cell adenoma is an uncommon benign salivary gland neoplasm, presenting isomorphic basaloid cells with a prominent basal cell layer.
  • Taking into account that basal cell adenomas represent 1% of all salivary gland tumors, being the majority of cases in the parotid glands, the goal of this paper is to report a case of basal cell adenoma of the upper lip arising from minor salivary gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):533-6 [16053874.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jun;63(6):805-10 [15944978.001]
  • [Cites] Diagn Cytopathol. 1999 Jul;21(1):30-4 [10405805.001]
  • [Cites] J Oral Pathol Med. 1996 Jan;25(1):1-4 [8850349.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):251-9 [8776422.001]
  • [Cites] Semin Diagn Pathol. 1996 May;13(2):95-103 [8734415.001]
  • [Cites] J Craniomaxillofac Surg. 2000 Feb;28(1):56-61 [10851675.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):834-5 [1401223.001]
  • [Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]
  • [Cites] Acta Otolaryngol Suppl. 1969;263:155-9 [5269030.001]
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2002 Nov-Dec;57(6):271-6 [12612759.001]
  • [Cites] Oral Oncol. 2001 Jun;37(4):365-8 [11337269.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 May;31B(3):197-201 [7549761.001]
  • (PMID = 19212550.001).
  • [ISSN] 1305-7456
  • [Journal-full-title] European journal of dentistry
  • [ISO-abbreviation] Eur J Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC2635906
  • [Keywords] NOTNLM ; Basal cell adenoma / Immunohistochemistry / Minor salivary gland
  •  go-up   go-down


3. Mărgăritescu C, Mercuţ V, Mogoantă L, Florescu M, Simionescu C, Cionca L, Manea M: Salivary gland Basal cell adenomas--immunohistochemical evaluation of four cases and review of the literature. Rom J Morphol Embryol; 2005;46(1):29-40
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland Basal cell adenomas--immunohistochemical evaluation of four cases and review of the literature.
  • OBJECTIVE: Evaluate the antigen profile of cellular population from basal cell adenomas.
  • MATERIAL AND METHODS: Histopathological and immunohistochemical evaluation of four-salivary gland basal cell adenomas; the pathological samples were provided by the Oral Maxilla Facial Surgery Department of the Clinical County Hospital from Craiova.
  • RESULTS: All basal cell adenoma exhibit differentiation toward 3 cell phenotypes: ductal luminal, basal and myoepithelial.
  • CONCLUSIONS: The antigen profile of these tumors closely regard with other variants of salivary gland adenomas, such as pleomorphic adenoma and myoepithelioma.
  • [MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Proliferating Cell Nuclear Antigen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286982.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  • [Number-of-references] 66
  •  go-up   go-down


Advertisement
4. Antoniades D, Epivatianos A, Markopoulos A, Kolokotronis A, Zaraboukas T: Coexistence of mucous retention cyst and basal cell adenoma arising from the lining epithelium of the cyst. Report of two cases. Med Princ Pract; 2009;18(3):248-52
MedlinePlus Health Information. consumer health - Salivary Gland Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of mucous retention cyst and basal cell adenoma arising from the lining epithelium of the cyst. Report of two cases.
  • OBJECTIVE: To report 2 cases of coexisting mucous retention cyst and basal cell adenoma arising from the lining epithelium of the cyst.
  • CLINICAL PRESENTATION AND INTERVENTION: Two cases of painless swellings, well-demarcated, soft to palpation, and located in the submucosa of the upper lip were clinically examined with the provisional diagnosis of mucocele or salivary gland tumor.
  • Histological examination showed the presence of a large unilocular cystic cavity in many parts surrounded by single or bilayered lining epithelium composed of flattened to cuboidal cells, and in other parts surrounded by projections of cells arranged in a trabecular pattern far into the cystic cavity.
  • The trabeculae were composed of basal and low columnar cells that sometimes formed small duct-like structures.
  • Based on the results, a diagnosis of coexisting mucous retention cysts and basal cell adenomas arising from the lining epithelium of cysts was made.
  • CONCLUSION: The coexistence of mucous retention cysts and basal cell adenomas arising from the lining epithelium of the cyst is reported.
  • [MeSH-major] Adenoma / complications. Adenoma / pathology. Mucocele / complications. Mucocele / pathology. Salivary Gland Diseases / complications. Salivary Gland Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19349732.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


5. Okahara M, Kiyosue H, Matsumoto S, Hori Y, Tanoue S, Uchida D, Mori H, Kondo Y: Basal cell adenoma of the parotid gland: MR imaging findings with pathologic correlation. AJNR Am J Neuroradiol; 2006 Mar;27(3):700-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland: MR imaging findings with pathologic correlation.
  • BACKGROUND AND PURPOSE: Basal cell adenomas (BCAs) are rare tumors of the parotid gland.
  • The aim of this study was to describe and characterize the MR findings of BCAs of the parotid gland.
  • [MeSH-major] Adenoma / pathology. Magnetic Resonance Imaging. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552019.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Hara H, Oyama T, Saku T: Fine needle aspiration cytology of basal cell adenoma of the salivary gland. Acta Cytol; 2007 Sep-Oct;51(5):685-91
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of basal cell adenoma of the salivary gland.
  • OBJECTIVE: To formulate cytologic features for differential diagnosis of basal cell adenoma (BCA).
  • STUDY DESIGN: The usefulness of 5 items for a cytologically definitive diagnosis of BCA was examined.
  • The 5 items in 8 BCA and 22 non-BCA cases (adenoid cystic carcinoma [ADCC], basal cell adenocarcinoma, myoepithelioma, pleomorphic adenoma and polymorphous low-grade adenocarcinoma) that displayed mimicking cytology were examined cytologically.
  • RESULTS: The useful items were < 5.1 microm in mean of epithelial nuclear short diameter; mild atypia on definitive diagnosis; stromal cell cluster combining smooth margin surrounding the epithelial cell cluster or containing the epithelial cell cluster; epithelial clusters surrounded by or adhered to a thick, hyalinized smooth margin without stromal cluster; and closely fastened, tight clusters with denser cytoplasm than ADCC, but an indistinct border, with oval nuclei and no hyaline cells.
  • [MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy, Fine-Needle. Carcinoma, Adenoid Cystic / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Epithelium / pathology. Epithelium / ultrastructure. Humans. Immunohistochemistry. Myoepithelioma / pathology. Organelle Size. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910337.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Kuratomi Y, Satoh S, Hayashida S, Inokuchi A: Basal cell adenoma and lymphoepithelial cyst as recurrent tumors of pleomorphic adenoma of the parotid gland. Auris Nasus Larynx; 2006 Mar;33(1):97-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma and lymphoepithelial cyst as recurrent tumors of pleomorphic adenoma of the parotid gland.
  • Basal cell adenoma of the parotid gland is a rare benign tumor.
  • Lymphoepithelial cyst of the parotid gland is also a rare benign tumor-like lesion.
  • We report an elderly woman, who previously underwent a removal of pleomorphic adenoma, with multiple masses in the left parotid gland.
  • Physical, MR and intra-operative examination suggested the masses as multiple recurrences of the previous pleomorphic adenoma.
  • The histological examination revealed that the masses were two basal cell adenomas and one lymphoepithelial cyst.
  • These rare tumors should be considered in the differential diagnosis of recurrent masses after a removal of pleomorphic adenoma of the parotid gland.
  • [MeSH-major] Adenoma / pathology. Adenoma, Pleomorphic / pathology. Branchioma / pathology. Neoplasms, Second Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171964.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Lee DK, Chung KW, Baek CH, Jeong HS, Ko YH, Son YI: Basal cell adenoma of the parotid gland: characteristics of 2-phase helical computed tomography and magnetic resonance imaging. J Comput Assist Tomogr; 2005 Nov-Dec;29(6):884-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland: characteristics of 2-phase helical computed tomography and magnetic resonance imaging.
  • OBJECTIVE: The goal of this study was to report the radiologic characteristics of basal cell adenoma of the parotid gland, which is a relatively rare neoplasm.
  • METHODS: A radiology and otolaryngology specialist reviewed the 2-phase helical computed tomography (CT) (n = 6) and/or magnetic resonance (MR) imaging (n = 2) scans of 7 patients with basal cell adenoma.
  • CONCLUSIONS: Basal cell adenomas of the parotid gland present as small well-marginated tumors and appear as masses with central large cysts or solid masses with microcysts on CT and MR imaging scans.
  • Basal cell adenomas of the parotid gland had at least 2 different enhancement patterns on the 2-phase helical CT scans, and the enhancement patterns and imaging architecture were related to the histologic subtype of the tumors.
  • [MeSH-major] Adenoma / diagnosis. Magnetic Resonance Imaging / methods. Parotid Gland / pathology. Parotid Gland / radiography. Parotid Neoplasms / diagnosis. Tomography, Spiral Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16272868.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; JR13W81H44 / Iopamidol
  •  go-up   go-down


9. Chawla AJ, Tan TY, Tan GJ: Basal cell adenomas of the parotid gland: CT scan features. Eur J Radiol; 2006 May;58(2):260-5
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenomas of the parotid gland: CT scan features.
  • Basal cell adenoma (BCA) is a rare tumor of the parotid gland, and except for a few case reports, the imaging features of this pathological entity are not well described.
  • [MeSH-major] Adenoma / diagnosis. Parotid Gland / radiography. Parotid Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Radiographic Image Enhancement / methods. Rare Diseases. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16414228.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


10. Chiu NC, Wu HM, Chou YH, Li WY, Chiou YY, Guo WY, Chang CY: Basal cell adenoma versus pleomorphic adenoma of the parotid gland: CT findings. AJR Am J Roentgenol; 2007 Nov;189(5):W254-61
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma versus pleomorphic adenoma of the parotid gland: CT findings.
  • OBJECTIVE: Basal cell adenoma is a rare benign epithelial tumor of the salivary gland.
  • The objective of this study is to present the CT findings of parotid basal cell adenoma.
  • We also compare CT findings of basal cell adenoma with those of pleomorphic adenoma, the most common parotid tumor, to determine whether any features on CT can help differentiate these two entities.
  • CONCLUSION: Basal cell adenomas of the parotid gland are located chiefly in the superficial lobe.
  • The age of the patient and the attenuation on unenhanced and contrast-enhanced CT may help in differentiating basal cell adenoma from pleomorphic adenoma of the parotid gland.
  • [MeSH-major] Adenoma / radiography. Adenoma, Pleomorphic / radiography. Parotid Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954621.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Yang GC, Waisman J: Distinguishing adenoid cystic carcinoma from cylindromatous adenomas in salivary fine-needle aspirates: the cytologic clues and their ultrastructural basis. Diagn Cytopathol; 2006 Apr;34(4):284-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing adenoid cystic carcinoma from cylindromatous adenomas in salivary fine-needle aspirates: the cytologic clues and their ultrastructural basis.
  • The utilization of fine-needle aspiration (FNA) biopsy in salivary tumors is hindered by the reluctance of many cytopathologists to report adenoid cystic carcinoma (ACC) because its cylindromatous stroma is observed occasionally in pleomorphic adenoma (PA) and basal cell adenoma (BA), and a diagnosis of ACC results in radical surgery.
  • The cytoplasm of majority of neoplastic cells of ACCs are invisible, because the thin rim of cytoplasm measured <1 microm ultrastructurally, well beyond the resolution of a light microscope.
  • In conclusion, in our analysis of salivary tumors with a cylindromatous pattern, the seemingly naked nuclei of neoplastic cells with their coarse nuclear chromatin and irregular nucleoli, as revealed by the UFP stain, reliably distinguished ACC from cylindromatous adenomas.
  • [MeSH-major] Adenoma / pathology. Adenoma / ultrastructure. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / ultrastructure. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16544336.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Bilić M, Kovać L, Prgomet D, Krizanac S: [Basal cell adenoma of the nasal septum: a case report]. Lijec Vjesn; 2008 Jan-Feb;130(1-2):13-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell adenoma of the nasal septum: a case report].
  • [Transliterated title] Adenom bazalnih stanica nosnog septuma prikaz bolesnika.
  • This article reports a case of an intranasal basal cell adenoma, which is an extremely rare tumor and comprises only 1 to 3% of salivary gland neoplasms.
  • Immunohistochemically the diagnosis of basal cell adenoma was confirmed.
  • This location of basal cell adenoma has not yet been described in the recent literature.
  • [MeSH-major] Adenoma. Nasal Septum. Nose Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18589637.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


13. Farah-Klibi F, Ferchiou M, Kourda J, El Amine O, Ferjaoui M, Ben Jilani S, Zermani R: [Parotid basal cell adenoma of membranous type]. Tunis Med; 2009 Feb;87(2):149-51
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parotid basal cell adenoma of membranous type].
  • [Transliterated title] Adenome a cellules basales de type membraneux de la parotide.
  • INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.
  • AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.
  • So the diagnosis of metastatic malignant salivary gland tumor was suspected.
  • Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.
  • CONCLUSION: The BCA is a benign tumor located generally in the parotid gland.
  • When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis. Sarcoidosis / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Mediastinum / radiography. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522450.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


14. Ozcan C, Apa DD, Vayisoglu Y, Görür K: Unilateral parotid gland involvement with synchronous multiple Basal cell adenomas. J Craniofac Surg; 2007 Nov;18(6):1470-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral parotid gland involvement with synchronous multiple Basal cell adenomas.
  • Basal cell adenoma (BCA) is a rare benign epithelial tumor of the salivary gland.
  • BCA is seen most frequently in the parotid gland and less commonly in the submandibular gland and minor glands of the upper lips, oral cavity, and hard palate.
  • Salivary gland tumors are observed as single tumors in one salivary gland.
  • Double or multiple tumors of the salivary gland tumors are unusual and metachronous or bilateral salivary gland tumors are more observed than synchronous or unilateral tumors.
  • Physical examination revealed two solid and well-delineated masses in the preauricular region, which were 1.5 x 1 cm in diameter and in the tail of the parotid gland, which is 2.5 x 2 cm in diameter.
  • Excision of the superficial lobe of the parotid gland was performed.
  • Multiple synchronous nonmembranous-type BCAs of the unilateral parotid gland is a rare entity.
  • More extensive excision of the parotid gland tumor, careful macroscopic perioperative examination of the surgical specimen, and histologic evaluation of all surgical specimens might be necessary for reducing revision operations and surgical complications.
  • [MeSH-major] Adenoma / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Adenolymphoma / diagnosis. Aged. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993904.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. González-García R, Nam-Cha SH, Muñoz-Guerra MF, Gamallo-Amat C: Basal cell adenoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E206-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland. Case report and review of the literature.
  • Basal cell adenoma of the salivary glands is an uncommon type of monomorphous adenoma.
  • Its most frequent location is the parotid gland.
  • Histologically, isomorphic cells in nests and interlaced trabecules with a prominent basal membrane are observed.
  • It is also characterized by the presence of a slack and hyaline stroma and the absence of myxoid or condroid stroma.
  • In contrast to pleomorphic adenoma, it tends to be multiple and its recurrence rate after surgical excision is high.
  • Due to prognostic implications, differential diagnosis with basal cell adenocarcinoma, adenoid cystic carcinoma and basaloid squamous cell carcinoma is mandatory.
  • We describe a case of basal cell adenoma of the parotid gland.
  • We also review the literature and discuss the diagnosis and management of this rare entity.
  • [MeSH-major] Adenoma / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505803.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


16. Yerli H, Teksam M, Aydin E, Coskun M, Ozdemir H, Agildere AM: Basal cell adenoma of the parotid gland: dynamic CT and MRI findings. Br J Radiol; 2005 Jul;78(931):642-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland: dynamic CT and MRI findings.
  • Imaging findings in basal cell adenoma (BCA) of the parotid gland have been rarely reported.
  • We report dynamic CT and MRI findings of BCA in the parotid gland in a 78-year-old woman.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15961849.001).
  • [ISSN] 0007-1285
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Kawahara A, Harada H, Akiba J, Yokoyama T, Kage M: Fine-needle aspiration cytology of basal cell adenoma of the parotid gland: characteristic cytological features and diagnostic pitfalls. Diagn Cytopathol; 2007 Feb;35(2):85-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of basal cell adenoma of the parotid gland: characteristic cytological features and diagnostic pitfalls.
  • We retrospectively studied the cytological features of aspiration cytology in 12 cases of basal cell adenoma (BCA) and 5 cases mistakenly diagnosed as BCA.
  • The characteristic cytological features of solid type BCA were three-dimensional clusters in 71%, sharp-angle small clusters in 86%, basement membrane- like material in 71%, and cell crush in 86%.
  • In contrast, 3 of the 5 cystic type BCA cases showed inadequate cellular components or no basaloid tumor cells, and the cytological diagnosis of BCA could not be determined.
  • In the 5 cases misdiagnosed as BCA, there were 2 cases of pleomorphic adenoma, 2 cases of benign lymphoepithelial cyst, and 1 case of basal cell adenocarcinoma.
  • Accurate differential cytological diagnosis of BCA is relatively easy to determine the solid type BCA, but is more difficult for cystic type BCA.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230571.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kawata R, Yoshimura K, Lee K, Araki M, Takenaka H, Tsuji M: Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor. Eur Arch Otorhinolaryngol; 2010 May;267(5):779-83
Genetic Alliance. consumer health - Warthin's tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland: a clinicopathological study of nine cases--basal cell adenoma versus pleomorphic adenoma and Warthin's tumor.
  • The aim of this study is to investigate the clinical and pathological characteristics of basal cell adenoma (BCA) and to compare the diagnosis/treatment of BCA with those of Warthin's tumor (WT) and pleomorphic adenoma (PA).
  • Among 192 patients with benign tumors of the parotid gland who underwent surgery, 9 had BCA.
  • The accuracy of fine needle aspiration biopsy (FNAB) for diagnosis of BCA was slightly lower than for PA and WT.
  • Most PA and BCA lesions developed in the upper part of the parotid gland.
  • When PA and WT are ruled out by FNAB after a tentative diagnosis of benign tumor has been based on imaging findings, BCA should be considered.
  • [MeSH-major] Adenolymphoma / pathology. Adenoma / pathology. Adenoma, Pleomorphic / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 2007 Feb;35(2):85-90 [17230571.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • [Cites] Arch Klin Exp Ohren Nasen Kehlkopfheilkd. 1967;189(3):302-16 [5595712.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):260-4 [15468947.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):736-45 [6284339.001]
  • [Cites] Br J Radiol. 2005 Jul;78(931):642-5 [15961849.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar 01;11(2):E206-9 [16505803.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]
  • (PMID = 19908055.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Veeresh M, Bavle RM, Vinay KN, Nandakumar H: Basal cell adenoma of the submandibular gland. J Maxillofac Oral Surg; 2010 Sep;9(3):289-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the submandibular gland.
  • Basel cell adenoma is a benign epithelial salivary gland tumor that appears to have unique histologic characteristics.
  • The diagnosis of this entity must be established by histological study.
  • It commonly occurs in parotid gland and very rarely in submandibular gland.
  • Here we report a case of basel cell adenoma of submandibular gland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22190808.001).
  • [ISSN] 0974-942X
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3177454
  • [Keywords] NOTNLM ; Adenoma / Basal cells / Submandibular gland
  •  go-up   go-down


20. Gupta N, Jadhav K, Ahmed MB, Amberkar VS: Basal cell adenoma in a relatively rare site. J Oral Maxillofac Pathol; 2009 Jul;13(2):101-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma in a relatively rare site.
  • Basal cell adenoma (BCA) of the salivary glands is an uncommon type of monomorphic adenoma.
  • Its most frequent location is the parotid gland.
  • Histologically, it is seen as nests of isomorphic cells and interlaced trabeculae with a prominent basal membrane.
  • There is also slack, hyaline stroma with absence of a myxoid or chondroid component.
  • We describe a case of BCA of palatal minor salivary glands, a rare site for its occurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1982 May;13(5):497-500 [7076228.001]
  • [Cites] Semin Diagn Pathol. 1987 May;4(2):117-35 [3313598.001]
  • [Cites] Br J Radiol. 2005 Jul;78(931):642-5 [15961849.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):260-4 [15468947.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Ann Diagn Pathol. 2003 Oct;7(5):292-5 [14571431.001]
  • [Cites] J Laryngol Otol. 2000 Jan;114(1):83-5 [10789423.001]
  • [Cites] J Laryngol Otol. 1997 Feb;111(2):182-5 [9102452.001]
  • [Cites] Eur J Dent. 2008 Jul;2(3):213-6 [19212550.001]
  • (PMID = 21887012.001).
  • [ISSN] 0973-029X
  • [Journal-full-title] Journal of oral and maxillofacial pathology : JOMFP
  • [ISO-abbreviation] J Oral Maxillofac Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3162860
  • [Keywords] NOTNLM ; Basal cell adenoma / alpha smooth muscle actin / monomorphic adenoma / pancytokeratin / squamous morules
  •  go-up   go-down


21. Rudolph J, Berl J, Hamm B, Klingebiel R: Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy. Acta Radiol; 2006 Mar;47(2):205-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy.
  • We present the magnetic resonance imaging in the unusual combination of a patient with known myotonic dystrophy and recurrent basal cell tumor.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Basal Cell / diagnosis. Head and Neck Neoplasms / diagnosis. Magnetic Resonance Imaging. Myotonic Dystrophy / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Myotonic dystrophy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604969.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


22. Nakabayashi M, Shomori K, Kiya S, Shiomi T, Nosaka K, Ito H: Tubular-trabecular type Basal cell adenoma of the parotid gland: a patient report. Yonago Acta Med; 2010 Sep;53(3):65-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular-trabecular type Basal cell adenoma of the parotid gland: a patient report.
  • Basal cell adenoma (BCA) is an uncommon benign salivary gland neoplasm that includes isomorphic basaloid cells.
  • We report on a female patient with BCA that developed in the right parotid gland in her 50s.
  • We could achieve an accurate diagnosis of BCA by immunohistochemistry with MIB-1 and other markers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24031120.001).
  • [ISSN] 0513-5710
  • [Journal-full-title] Yonago acta medica
  • [ISO-abbreviation] Yonago Acta Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC3763784
  • [Keywords] NOTNLM ; basal cell adenoma / immunohistochemistry / parotid gland
  •  go-up   go-down


23. Fracchia M, Galatola G, Sarotto I, Guraldo V, Perona M, Pera A, Risio M: Serum bile acids, programmed cell death and cell proliferation in the mucosa of patients with colorectal adenomas. Dig Liver Dis; 2005 Jul;37(7):509-14
Hazardous Substances Data Bank. DEOXYCHOLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum bile acids, programmed cell death and cell proliferation in the mucosa of patients with colorectal adenomas.
  • BACKGROUND: Deoxycholic acid induced programmed cell death and an imbalance with cell proliferation may favour colorectal tumourigenesis according to 'in vitro' studies, but information is lacking on the relationships occurring 'in vivo' in humans.
  • AIMS: To evaluate whether serum deoxycholic acid is associated with programmed cell death and cell proliferation in colonic mucosa.
  • METHODS: In 10 patients with colorectal adenomas, we measured fasting serum levels of bile acids; and, in normal colonic mucosa, programmed cell death by the TUNEL technique and cell proliferation by immunohistochemical staining with anti-Ki67.
  • RESULTS: Among serum bile acids, only total deoxycholic acid (median: 0.89 micromol/L +/- 0.54 95% CI), showed a significant positive correlation with the total and basal compartments PCD Index (r = 0.68, p < 0.05).
  • Within the median compartment of the crypt, cell proliferation was negatively associated with all unconjugated bile acids.
  • CONCLUSIONS: The positive association between deoxycholic acid and programmed cell death in the basal compartment of the crypt, and the negative association of cell proliferation and unconjugated bile acids in the median compartment, do not seem to support the co-carcinogenic effect of deoxycholic acid.
  • [MeSH-major] Adenoma / blood. Apoptosis / drug effects. Bile Acids and Salts / blood. Cell Proliferation / drug effects. Colorectal Neoplasms / blood. Deoxycholic Acid / blood. Deoxycholic Acid / pharmacology. Intestinal Mucosa / cytology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975538.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Bile Acids and Salts; 0 / Ki-67 Antigen; 0 / MIB-1 antibody; 005990WHZZ / Deoxycholic Acid
  •  go-up   go-down


24. Acunzo J, Thirion S, Roche C, Saveanu A, Gunz G, Germanetti AL, Couderc B, Cohen R, Figarella-Branger D, Dufour H, Brue T, Enjalbert A, Barlier A: Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res; 2008 Dec 15;68(24):10163-70
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.
  • In human somatotroph adenomas, growth hormone (GH) hypersecretion can be inhibited by somatostatin analogues such as octreotide.
  • In this present study, the sst2 gene was transferred by an adenoviral vector (Ad-sst2) in human somatotroph (n = 7) and lactotroph (n = 2) adenomas in vitro.
  • Ten days after infection at 20 multiplicity of infection (MOI), sst2 gene transfer decreased cell viability from 19% to 90% by caspase-dependent apoptosis.
  • At low viral doses (5 MOI), Ad-sst2 decreased GH or prolactin (PRL) basal secretion and mRNA expression.
  • Four days after infection by 5 MOI Ad-sst2, the maximal GH suppression by octreotide increased from 31% to 57% in the octreotide partially resistant group and from 0% to 27% in the resistant ones.
  • Finally, lactotroph tumors, nonresponding to octreotide in basal conditions, became octreotide sensitive with a maximal PRL suppression of 43% at 10(-8) mol/L.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Human Growth Hormone / secretion. Octreotide / pharmacology. Pituitary Neoplasms / drug therapy. Prolactin / secretion. Prolactinoma / drug therapy
  • [MeSH-minor] Adenoviridae / genetics. Cell Survival / physiology. Drug Resistance, Neoplasm. Humans. Immunohistochemistry. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Somatostatin / biosynthesis. Receptors, Somatostatin / genetics. Transduction, Genetic. Transgenes

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Guide to Pharmacology. gene/protein/disease-specific - sst2 receptor - data and references .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074883.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


25. Heyl J, Mehregan D: Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas. J Cutan Pathol; 2008 Jan;35(1):40-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas.
  • BACKGROUND: Distinction between sebaceous tumors and basal cell carcinomas can often pose diagnostic problems.
  • Our aim was to evaluate the use of CK 19 staining patterns in differentiating between sebaceous tumors and basal cell carcinomas.
  • The sebaceous tumors that were examined in this study included sebaceous adenomas, sebaceous epitheliomas (sebaceomas) and sebaceous carcinomas.
  • METHODS: Thirty-seven cases including 5 sebaceous adenomas, 16 sebaceous epitheliomas, 6 sebaceous carcinomas and 14 basal cell carcinomas (7 being of the morpheaform type and 7 nodular basal cell carcinomas) were tested with a monoclonal mouse antibody to human CK 19.
  • RESULTS: CK 19 was focally positive in 1/5 (20%) sebaceous adenomas, 8/16 (50%) of sebaceous epitheliomas and 1/6 (17%) of sebaceous carcinomas.
  • Strongly positive expression of CK 19 was not seen in any of the sebaceous adenoma, sebaceous epithelioma or sebaceous carcinoma specimens.
  • CK 19 was found to be strongly positive in 9/14 (64%) and focally positive in 2/14 (14%) of basal cell carcinomas.
  • CONCLUSION: CK 19 expression can be helpful in differentiating sebaceous tumors (including sebaceous adenomas, sebaceous epitheliomas and sebaceous carcinomas) from basal cell carcinomas and may be a useful adjunct when these entities are included in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Keratin-19 / analysis. Sebaceous Gland Neoplasms / diagnosis. Sebaceous Glands / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095993.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19
  •  go-up   go-down


26. Yang HM, Cabral E, Dadras SS, Cassarino DS: Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas. Am J Dermatopathol; 2008 Dec;30(6):549-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of D2-40 in benign and malignant sebaceous tumors and comparison to basal and squamous cell carcinomas.
  • The diagnosis of sebaceous carcinoma presents an important challenge to both clinicians and pathologists, as many cases are initially misdiagnosed both clinically and histopathologically, potentially leading to adverse medical and legal outcomes.
  • We studied the expression of D2-40 (podoplanin) by immunohistochemistry to determine if it can aid in this differential diagnosis and to evaluate the possibility of lymphangiogenesis in sebaceous carcinoma.
  • A total of 36 cases of sebaceous lesions, including 16 sebaceous carcinomas, 7 sebaceous adenomas, 6 sebaceomas, and 7 cases of normal glands and sebaceous hyperplasia, and 17 cases of basal cell carcinoma and 10 cases of squamous cell carcinoma, were also examined.
  • We also found D2-40 to be only weakly and focally positive in basal cell carcinoma and weakly to moderately positive in squamous cell carcinoma, which showed increased staining with decreased differentiation.
  • Therefore, overall, D2-40 is, of limited diagnostic utility in sebaceous lesions but may be useful in distinguishing sebaceoma and basaloid sebaceous carcinoma from basal cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Sebaceous / metabolism. Antibodies, Monoclonal / metabolism. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Sebaceous Gland Neoplasms / metabolism. Sebaceous Glands / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / metabolism. Adenoma / pathology. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / metabolism. Case-Control Studies. Cell Proliferation. Diagnosis, Differential. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Hyperplasia / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033927.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


27. Scott AR, Faquin WC, Deschler DG: Parotid mass in a woman with multiple cutaneous cylindromas. Head Neck; 2010 May;32(5):684-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a woman with scalp lesions and a parotid mass.
  • METHODS: Biopsy of a skin nodule demonstrated cylindroma, and fine-needle aspiration of the parotid mass suggested membranous basal cell adenoma, which was confirmed following superficial parotidectomy.
  • RESULTS: Eighteen cases of cylindromatosis with coexistent salivary gland membranous basal cell adenoma were reported.
  • Seventeen cases involved the parotid gland; there are 2 reports of malignant transformation.
  • CONCLUSION: FADC should be considered in anyone with coexistent dermal and salivary gland neoplasms.
  • Membranous basal cell adenoma may be mistaken for adenoid cystic carcinoma on cytologic or histologic examination.
  • [MeSH-major] Adenoma / pathology. Carcinoma, Adenoid Cystic / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Female. Humans. Middle Aged. Parotid Gland / pathology. Parotid Gland / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455704.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Weinreb I, Simpson RH, Skálová A, Perez-Ordoñez B, Dardick I, Chetty R, Hunt JL: Ductal adenomas of salivary gland showing features of striated duct differentiation ('striated duct adenoma'): a report of six cases. Histopathology; 2010 Nov;57(5):707-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ductal adenomas of salivary gland showing features of striated duct differentiation ('striated duct adenoma'): a report of six cases.
  • AIMS: To describe a salivary adenoma composed largely of unilayered ducts resembling striated ducts, and to differentiate it from similar adenomas, including canalicular and intercalated duct adenoma.
  • METHODS AND RESULTS: Six unilayered ductal adenomas were identified in parotid (four) and palate (two).
  • Prominent cell membranes, reminiscent of 'striations' of normal striated ducts, were seen.
  • The typical epithelial 'beading' pattern with abundant stroma of canalicular adenoma was absent.
  • In contrast, the normal excretory and intercalated ducts all contained diffuse bilayering with basal or myoepithelial markers.
  • CONCLUSIONS: Striated duct adenomas are unilayered ductal tumours that recapitulate normal striated ducts.
  • [MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology
  • [MeSH-minor] Cell Differentiation. Humans. Male. Membrane Proteins / metabolism. Middle Aged. Muscle, Smooth / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 21054495.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


29. Miliauskas JR, Hunt JL: Primary unilateral multifocal pleomorphic adenoma of the parotid gland: molecular assessment and literature review. Head Neck Pathol; 2008 Dec;2(4):339-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary unilateral multifocal pleomorphic adenoma of the parotid gland: molecular assessment and literature review.
  • Multiple separate tumors developing in a single salivary gland is rare in previously untreated patients.
  • Tumors that can be multicentric include Warthin tumor, oncocytoma, basal cell adenoma and acinic cell carcinoma.
  • The incidence of multiple primary unilateral pleomorphic adenomas is extremely rare in patients with no prior history of trauma or surgery.
  • We report two cases of primary multicentric pleomorphic adenoma and review the literature.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Loss of Heterozygosity. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngorhinootologie. 2007 Jun;86(6):448-50 [17219338.001]
  • [Cites] Lab Invest. 2001 Sep;81(9):1289-97 [11555676.001]
  • [Cites] Ear Nose Throat J. 2002 May;81(5):341-5 [12025006.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Sep;33(6):531-4 [15308250.001]
  • [Cites] Arch Otolaryngol. 1966 Sep;84(3):329-31 [4287765.001]
  • [Cites] Am J Surg. 1969 Nov;118(5):787-9 [4310431.001]
  • [Cites] J Laryngol Otol. 1977 Jul;91(7):629-32 [197179.001]
  • [Cites] Laryngoscope. 1982 Nov;92(11):1265-8 [6292599.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1219-24 [2917323.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):431-5 [8630948.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jan;32B(1):3-7 [8729611.001]
  • [Cites] Cancer. 1953 Nov;6(6):1065-133 [13106826.001]
  • [Cites] Ann Otolaryngol. 1954;71(5-6):474-5 [13181211.001]
  • [Cites] Acta Otolaryngol Suppl. 1964;188:SUPPL 191:1-99 [14156485.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):498-503 [10821498.001]
  • (PMID = 20614306.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2807582
  • [Keywords] NOTNLM ; Multifocal / Parotid gland / Pleomorphic adenoma
  •  go-up   go-down


30. Weinreb I, Seethala RR, Hunt JL, Chetty R, Dardick I, Perez-Ordoñez B: Intercalated duct lesions of salivary gland: a morphologic spectrum from hyperplasia to adenoma. Am J Surg Pathol; 2009 Sep;33(9):1322-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intercalated duct lesions of salivary gland: a morphologic spectrum from hyperplasia to adenoma.
  • Intercalated duct lesions (IDLs) are rare, poorly understood and not well-studied lesions that have been associated with a small number of epithelial-myoepithelial carcinomas (EMC) and basal cell adenomas.
  • To examine the nature of IDLs and their association with salivary gland tumors, we reviewed 34 lesions in 32 patients.
  • The majorities of IDLs were parotid lesions (82%), were small and nodular (average size 3.1 mm) and showed 3 architectural patterns: hyperplasia (20), adenoma (9), and hybrid forms (5).
  • In 59% of cases, IDLs were seen in conjunction with another salivary gland tumor, most commonly basal cell adenoma (8 cases), followed by EMC (3 cases).
  • One case showed a combination of intercalated duct hyperplasia and basal cell adenoma.
  • Calponin and CK14 highlighted a thin myoepithelial cell layer around all ducts (100%).
  • In summary, IDLs have a variety of patterns ranging from hyperplasia to adenoma with hybrid lesions and share morphologic and immunophenotypic features with normal intercalated ducts.
  • There is an association with basal cell adenomas and EMC, which lends credence to their role as a putative precursor lesion.
  • [MeSH-major] Adenoma / pathology. Salivary Ducts / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Calcium-Binding Proteins / metabolism. Female. Humans. Hyperplasia. Keratins / metabolism. Male. Microfilament Proteins / metabolism. Middle Aged. Muramidase / metabolism. Neoplasms, Multiple Primary. Parotid Gland / metabolism. Parotid Gland / pathology. Parotid Gland / surgery. Receptors, Steroid / metabolism. S100 Proteins / metabolism. Submandibular Gland / metabolism. Submandibular Gland / pathology. Submandibular Gland / surgery. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542868.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / Receptors, Steroid; 0 / S100 Proteins; 0 / calponin; 68238-35-7 / Keratins; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


31. Sobota A, Pena M, Santi M, Ali Ahmed A: Undifferentiated sinonasal carcinoma in a patient with nevoid basal cell carcinoma syndrome. Int J Surg Pathol; 2007 Jul;15(3):303-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Undifferentiated sinonasal carcinoma in a patient with nevoid basal cell carcinoma syndrome.
  • Nevoid basal cell carcinoma syndrome is an autosomal dominant multisystem disorder characterized by developmental anomalies and occurrence of multiple basal cell carcinomas and other tumors in early childhood.
  • In this article, the authors report a case of a 19-year-old African American male with nevoid basal cell carcinoma syndrome and a history of medulloblastoma at age 2, meningioma at age 14, thyroid follicular adenomas with papillary carcinoma at age 15, and 2 basal cell carcinomas at ages 16 and 18.
  • Review of the literature reveals that this is the first case of SNUC occurring in a patient with nevoid basal cell carcinoma syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / complications. Carcinoma / etiology. Nose Neoplasms / etiology


32. Pisarek H, Pawlikowski M, Kunert-Radek J, Winczyk K: Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? Endokrynol Pol; 2010 Mar-Apr;61(2):178-81
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
  • INTRODUCTION: The immunohistochemical examination of somatostatin receptor (SSTR) subtypes expression in different endocrine tumours, including pituitary adenomas, revealed membranous or cytoplasmic distribution of SSTR1-5.
  • In an earlier study a positive correlation between the summarized score of SSTR2A + SSTR2B expressions and growth hormone (GH) response to octreotide administration was found, independently of receptor distribution within the cell.
  • The drop in GH was defined as the percentage of the basal value.
  • The pituitary adenomas from these patients were immunostained to determine the hormonal phenotype and expression of SSTR subtypes.
  • As a consequence, the SSTR-immunopositivity in cell cytoplasm is increased.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / pathology. Octreotide / pharmacology. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / pathology. Receptors, Somatostatin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464704.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


33. Yerli H, Agildere AM, Aydin E, Geyik E, Haberal N, Kaskati T, Oguz D, Ozluoglu LN: Value of apparent diffusion coefficient calculation in the differential diagnosis of parotid gland tumors. Acta Radiol; 2007 Nov;48(9):980-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of apparent diffusion coefficient calculation in the differential diagnosis of parotid gland tumors.
  • BACKGROUND: The differential diagnosis of parotid gland tumors is often difficult with conventional magnetic resonance imaging.
  • PURPOSE: To determine whether the calculation of the apparent diffusion coefficient (ADC) is valuable for making the differential diagnosis of parotid tumors.
  • The ADC of each tumor and each healthy parotid gland was calculated.
  • RESULTS: The following types of masses were identified: 11 Warthin tumors, nine pleomorphic adenomas, seven malignant tumors, one basal cell adenoma, and two benign cysts.
  • The mean ADC value for the Warthin tumors was 0.97+/-0.16 x 10(-3) mm(2)/s, for the pleomorphic adenomas was 1.74+/-0.37 x 10(-3) mm(2)/s, for the malignant tumors was 1.04+/-0.35 x 10(-3) mm(2)/s, and for the normal parotid glands was 0.34+/-0.20 x 10(-3) mm(2)/s.
  • The respective ADC value for the single basal cell adenoma was 1.40 x 10(-3) mm(2)/s.
  • Statistically significant differences were identified between the subjects with pleomorphic adenoma and those with another type of parotid tumor, and between subjects with healthy parotid glands and those with a tumor.
  • CONCLUSION: Calculating the ADC appears to be useful in differentiating pleomorphic adenomas from other types of parotid gland tumors.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Case-Control Studies. Diagnosis, Differential. Echo-Planar Imaging / methods. Female. Humans. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957512.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


34. Sakamoto K, Ono T, Nakamura Y, Harada H, Nakashima T: Expression of cluster of differentiation 9 glycoprotein in benign and malignant parotid gland tumours. J Laryngol Otol Suppl; 2009;(31):58-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cluster of differentiation 9 glycoprotein in benign and malignant parotid gland tumours.
  • OBJECTIVES: This study aimed to clarify the significance of cluster of differentiation 9 glycoprotein gene expression in human parotid gland tumours.
  • METHODS: We retrospectively analysed immunohistochemical staining for cluster of differentiation 9 glycoprotein in parotid gland tumours.
  • RESULTS: Cluster of differentiation 9 glycoprotein was consistently detected in the normal parotid gland.
  • Regarding benign parotid gland tumours, cluster of differentiation 9 glycoprotein was present in 13 of 18 pleomorphic adenomas, in all Warthin tumours tested (21/21) and in all cases of basal cell adenoma tested (four of four).
  • Cluster of differentiation 9 glycoprotein was present in 11 of 14 mucoepidermoid carcinomas, in two of five acinic cell carcinomas and in two of five adenoid cystic carcinomas.
  • CONCLUSIONS: There was a statistically significantly reduced expression of cluster of differentiation 9 glycoprotein in malignant parotid gland tumours, compared with benign parotid gland tumours (p < 0.05).
  • These results suggest that a low level of cluster of differentiation 9 glycoprotein expression in parotid gland tumours may be associated with malignancy.
  • [MeSH-major] Antigens, CD / analysis. Membrane Glycoproteins / analysis. Neoplasm Proteins / analysis. Parotid Gland / chemistry. Parotid Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460206.001).
  • [ISSN] 0144-2945
  • [Journal-full-title] The Journal of laryngology and otology. Supplement
  • [ISO-abbreviation] J Laryngol Otol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD9; 0 / CD9 protein, human; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins
  •  go-up   go-down


35. Yerli H, Aydin E, Coskun M, Geyik E, Ozluoglu LN, Haberal N, Kaskati T: Dynamic multislice computed tomography findings for parotid gland tumors. J Comput Assist Tomogr; 2007 Mar-Apr;31(2):309-16
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic multislice computed tomography findings for parotid gland tumors.
  • OBJECTIVE: Our aim was to research the enhancement features of parotid gland masses in detail and characterize if the masses were Warthin tumors, adenomas, or malignant tumors.
  • RESULTS: There were 11 Warthin tumors, 8 pleomorphic adenomas, 5 malignant tumors, and 1 basal cell adenoma.
  • The basal cell adenoma showed also a peak enhancement at 30 seconds.
  • Seven pleomorphic adenomas showed increased enhancement through the first 3 phases.
  • Increased enhancement through all phases might be an indicator for diagnosing pleomorphic adenomas.
  • [MeSH-major] Adenolymphoma / diagnosis. Adenoma / diagnosis. Carcinoma / diagnosis. Lymphoma / diagnosis. Parotid Gland / radiography. Parotid Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prospective Studies. Radiographic Image Enhancement / methods. Time Factors. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414771.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


36. Tagliati F, Gentilin E, Buratto M, Molè D, degli Uberti EC, Zatelli MC: Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli. Endocrinology; 2010 Oct;151(10):4635-42
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli.
  • We here report the identification of a cDNA, corresponding to Magmas gene (mitochondria-associated protein involved in granulocyte-macrophage colony-stimulating factor signal transduction), which is highly expressed in two different ACTH-secreting mouse pituitary adenoma cell lines as compared with normal pituitary as well as in two thirds of 64 examined pituitary adenomas as compared with human normal pituitary.
  • Tim 16, the mitochondrial protein encoded by Magmas, was indeed expressed in a mouse ACTH-secreting pituitary adenoma cell line, AtT-20 D16v-F2 cells, in a subcellular compartment likely corresponding to mitochondria.
  • Moreover, Magmas-silenced cells displayed basal caspase 3/7 activity and DNA fragmentation levels similar to control cells, which both increased under proapoptotic stimuli.
  • Our data demonstrate that Magmas is overexpressed in mouse and human ACTH-secreting pituitary adenomas.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / genetics. Adenoma / genetics. Apoptosis / genetics. Mitochondrial Proteins / physiology
  • [MeSH-minor] Animals. Cell Proliferation. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Cells, Cultured. Cytoprotection / drug effects. Cytoprotection / genetics. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Pituitary Gland / metabolism. RNA, Small Interfering / pharmacology. Up-Regulation / drug effects

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20719856.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitochondrial Proteins; 0 / RNA, Small Interfering; 0 / magmas protein, human
  •  go-up   go-down


37. Neves Cde O, Soares AB, Costa AF, de Araujo VC, Furuse C, Juliano PB, Altemani A: CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):172-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms.
  • CD10 is a cell surface peptidase expressed in a wide variety of normal and neoplastic tissues, including breast myoepithelial cells.
  • In salivary glands, expression of CD10 has only been used to identify neoplastic myoepithelial cells of pleomorphic adenomas and myoepithelial carcinomas.
  • However, its accuracy in other salivary tumors with myoepithelial component has yet to be analyzed.
  • We examined 72 salivary tumors with myoepithelial differentiation using immunohistochemical technique to detect CD10.
  • In salivary glands, CD10 expression was not detected in myoepithelial cells.
  • Surprisingly, adenoid cystic carcinomas and basal cell adenomas were negative in 100% of the cases.
  • Myoepitheliomas, pleomorphic adenomas, and myoepithelial carcinomas were positive in 27.7%, 30.0%, and 40% of the cases, respectively.
  • In conclusion, salivary neoplastic myoepithelial cells gain CD10 expression in relation to their normal counterparts.
  • The high expression of CD10 by this carcinoma can be a valuable tool to separate EMEC from the tubular variant of adenoid cystic carcinomas in small incisional biopsies, where the precise diagnosis may be impossible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752720.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


38. Fernando MA, Heaney AP: Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol; 2005 Dec;19(12):3085-96
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas.
  • Doxazosin (dox), a selective alpha(1)-adrenergic receptor antagonist, used to treat hypertension, also inhibits prostate cancer cell proliferation.
  • We examined the effects of dox on murine and human pituitary tumor cell proliferation in vitro and in vivo. dox treatment inhibited proliferation of murine pituitary tumor cells, induced G(0)-G(1) cell cycle arrest, and reduced phosphorylated retinoblastoma levels.
  • In addition, increased annexin-fluorescein isothiocyanate immunoreactivity and cleaved caspase-3 levels, in keeping with dox-mediated apoptosis, were observed in the human and murine pituitary tumor cells, and dox administration to mice, harboring corticotroph tumors, decreased tumor growth and reduced plasma ACTH levels. dox-mediated antiproliferative and proapoptotic actions were not confined to alpha-adrenergic receptor-expressing pituitary tumor cells and were unaffected by cotreatment with the alpha-adrenergic receptor blocker, phenoxybenzamine. dox treatment led to reduced phosphorylated inhibitory kappaB (IkappaB)-alpha expression, and nuclear factor-kappaB transcription and decreased basal and TNFalpha-induced proopiomelanocortin transcriptional activation.
  • These results demonstrate that the selective alpha(1)-adrenergic receptor antagonist dox inhibits pituitary tumor cell growth in vitro and in vivo by mechanisms that are in part independent of its alpha-adrenergic receptor-blocking actions and involve down-regulation of nuclear factor-kappaB signaling. dox is proposed as a possible novel medical therapy for pituitary tumors.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / drug therapy. Adenoma / drug therapy. Adrenergic alpha-1 Receptor Antagonists. Adrenergic alpha-Antagonists / therapeutic use. Antineoplastic Agents / therapeutic use. Doxazosin / therapeutic use
  • [MeSH-minor] Adrenocorticotropic Hormone / blood. Animals. Apoptosis. Caspase 3. Caspases / metabolism. Cell Cycle / drug effects. Cell Proliferation / drug effects. Humans. I-kappa B Proteins / metabolism. Mice. Mice, Nude. NF-kappa B / metabolism. Neoplasm Transplantation. Pro-Opiomelanocortin / genetics. Receptors, Adrenergic, alpha-1 / genetics. Receptors, Adrenergic, alpha-1 / metabolism. Transcriptional Activation. Tumor Cells, Cultured. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020484.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Receptors, Adrenergic, alpha-1; 0 / Tumor Necrosis Factor-alpha; 139874-52-5 / NF-kappaB inhibitor alpha; 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; NW1291F1W8 / Doxazosin
  •  go-up   go-down


39. Mantovani G, Bondioni S, Ferrero S, Gamba B, Ferrante E, Peverelli E, Corbetta S, Locatelli M, Rampini P, Beck-Peccoz P, Spada A, Lania AG: Effect of cyclic adenosine 3',5'-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab; 2005 Dec;90(12):6721-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of cyclic adenosine 3',5'-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas.
  • OBJECTIVE: The objective of this study was to evaluate the effects of cAMP-PKA cascade activation in nonfunctioning pituitary adenomas (NFPA).
  • Cyclin D1 expression and ERK1/2 activity were analyzed under basal conditions and after cAMP-PKA cascade activation.
  • Moreover, in group 2, PKA blockade by the specific inhibitor PKI increased cyclin D1 expression (96 +/- 25% over basal) and ERK1/2 activity (116 +/- 28% over basal).
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / metabolism. Cyclic AMP / metabolism. Cyclic AMP-Dependent Protein Kinases / metabolism. Pituitary Neoplasms / metabolism. Pituitary Neoplasms / pathology
  • [MeSH-minor] Base Sequence. Cell Proliferation. Cyclic AMP-Dependent Protein Kinase RIalpha Subunit. Cyclin D1 / metabolism. Enzyme Activation. Humans. In Vitro Techniques. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Proteins / genetics. Proteins / metabolism. Receptors, Cell Surface / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16204369.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / PRKAR1A protein, human; 0 / Proteins; 0 / Receptors, Cell Surface; 136601-57-5 / Cyclin D1; E0399OZS9N / Cyclic AMP; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


40. Azevedo LR, Dos Santos JN, De Lima AA, Machado MA, Grégio AM: Canalicular adenoma presenting as an asymptomatic swelling of the upper lip: a case report. J Contemp Dent Pract; 2008;9(1):91-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canalicular adenoma presenting as an asymptomatic swelling of the upper lip: a case report.
  • AIM: The purpose of this report is to present the clinical and histological features of a canalicular adenoma (CA) occurring in the upper lip and vestibular fornix of a 62-year-old woman.
  • BACKGROUND: CA is an uncommon benign salivary gland tumor occurring almost exclusively in the intraoral glands.
  • This tumor has often been referred to as a variant of the basal cell adenoma.
  • However, the World Health Organization's latest histological classification of salivary gland tumors recognizes it as a separate entity under the broader heading of monomorphic adenoma, which is not related to any of the subtypes of basal cell adenomas.
  • Microscopic examination confirmed the final diagnosis of CA.
  • [MeSH-major] Adenoma / pathology. Lip Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176654.001).
  • [ISSN] 1526-3711
  • [Journal-full-title] The journal of contemporary dental practice
  • [ISO-abbreviation] J Contemp Dent Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Castro I, Lima L, Seoane R, Lado-Abeal J: Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas. Thyroid; 2009 Jun;19(6):645-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and functional characterization of two novel activating thyrotropin receptor mutants in toxic thyroid follicular adenomas.
  • BACKGROUND: Two previously unreported thyrotropin (TSH) receptor mutations, A623F and I635V, were identified in toxic follicular thyroid adenoma specimens from two patients with hyperthyroidism.
  • Our aim was to characterize both novel mutants in terms of the following: cAMP basal constitutive activity, cAMP response to TSH, plasma membrane expression levels, and TSH binding properties.
  • COS-7 cells were transiently transfected with wild-type and mutated TSH receptor constructs for determination of basal cAMP constitutive activity and dose-response accumulation of cAMP using recombinant human TSH.
  • RESULTS: Both mutants, A623F and I635V, had higher cAMP basal constitutive activities than the wild-type TSH receptor.
  • CONCLUSIONS: A623F and I635V are two naturally occurring TSH receptor mutations that increase basal cAMP accumulation and consequently promote the development of toxic follicular thyroid adenoma. cAMP response to increasing TSH dose is retained by A623F and I635V mutated receptors and the maximal stimulation obtained is not different from that of the wild-type receptor.
  • Substitution of alanine 623 by phenylalanine 623 at the third intracellular loop of the TSH receptor decreases its plasma membrane expression, indicating that alanine 623 is important in directing the TSH receptor to the cell surface or in down-regulating the constitutive receptor.
  • By contrast, isoleucine 635, located in the sixth transmembrane domain, is important in regulating TSH receptor basal activity but does not modify its plasma membrane expression.
  • [MeSH-major] Adenoma / genetics. Hyperthyroidism / genetics. Mutation / physiology. Receptors, Thyrotropin / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adult. Animals. Binding, Competitive. COS Cells. Cattle. Cercopithecus aethiops. Cyclic AMP / metabolism. DNA / genetics. Female. Flow Cytometry. Humans. Iodine Radioisotopes. Middle Aged. Receptors, Cell Surface / genetics. Thyrotropin / pharmacokinetics

  • Genetics Home Reference. consumer health - TSHR gene.
  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19499991.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Receptors, Cell Surface; 0 / Receptors, Thyrotropin; 9002-71-5 / Thyrotropin; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


42. Schapher M, Wendler O, Gröschl M, Schäfer R, Iro H, Zenk J: Salivary leptin as a candidate diagnostic marker in salivary gland tumors. Clin Chem; 2009 May;55(5):914-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary leptin as a candidate diagnostic marker in salivary gland tumors.
  • BACKGROUND: Since the discovery of autonomous leptin production in salivary glands, very few studies have reported on the physiological or pathological meaning of this particular cytokine in saliva.
  • The aim of this study was to investigate the expression of leptin and its receptors Ob-Ra and Ob-Rb in parotid salivary gland tumors, with particular regard to a potential use of leptin as a tumor marker.
  • METHODS: Parotid tissue samples from healthy individuals (n = 31) and tumor patients (n = 97, including tissue samples from pleomorphic adenomas, adenolymphomas, basal cell adenomas, and diverse carcinomas) were analyzed by use of ApoTome-technique microscopy, immunohistochemistry, immunofluorescence, immunoblotting, and quantitative real-time PCR.
  • Salivary and plasma leptin concentrations were measured by using ELISA.
  • RESULTS: In all salivary gland tumors leptin was expressed in much higher amounts than in healthy parotid tissues.
  • Immunoblotting results indicated that leptin was present as oligomers in salivary glands.
  • Measured leptin concentrations in mixed saliva samples were significantly increased in patients with parotid tumors [mean (SD) 673 (484) pg/mL in pleomorphic adenomas, 679 (465) pg/mL in adenolymphomas, and 880 (618) pg/mL in carcinomas] vs controls [125 (36) pg/mL] (P < 0.001).
  • CONCLUSIONS: This is the first study to show that the analysis of salivary leptin in mixed saliva samples may allow preoperative differentiation between tumor patients and healthy individuals.
  • [MeSH-minor] Adenolymphoma / diagnosis. Adenolymphoma / metabolism. Adenolymphoma / pathology. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adiponectin / biosynthesis. Adiponectin / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Enzyme-Linked Immunosorbent Assay. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Leptin / biosynthesis. Receptors, Leptin / genetics. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19299541.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin; 0 / Biomarkers, Tumor; 0 / Leptin; 0 / RNA, Messenger; 0 / Receptors, Leptin; 0 / leptin receptor, human
  •  go-up   go-down


43. Kazakov DV, Benkova K, Michal M, Vanecek T, Kacerovska D, Skalova A: Skin type spiradenoma of the parotid gland with malignant transformation: report of a case with analysis of the CYLD gene. Hum Pathol; 2009 Oct;40(10):1499-503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin type spiradenoma of the parotid gland with malignant transformation: report of a case with analysis of the CYLD gene.
  • A distinctive variant of basal cell adenoma called membranous basal cell adenoma is well recognized in salivary glands.
  • We present a case of a tumor involving the parotid gland that appeared identical to cutaneous spiradenoma.
  • In addition, the lesion had a malignant component identical to basal cell adenocarcinoma.
  • This is the first report of a "dermal analogue tumor" of the salivary gland that resembled a cutaneous spiradenoma and not a cylindroma.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Adenoid Cystic / genetics. Parotid Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. DNA Mutational Analysis. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454360.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


44. Markkanen-Leppänen M, Mäkitie AA, Passador-Santos F, Leivo I, Hagström J: Bilateral Basal cell adenocarcinoma of the parotid gland: in a recipient of kidney transplant. Clin Med Insights Pathol; 2010 Feb 18;3:1-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Basal cell adenocarcinoma of the parotid gland: in a recipient of kidney transplant.
  • We report a rare case of bilateral basal cell adenocarcinoma (BcAC) of the parotid gland in a male patient 30 years after kidney transplantation and continuous administration of immunosuppressive therapy.
  • BcAC is a salivary gland malignancy first recognized as a distinct neoplastic entity in WHO classification of salivary gland tumours in 1991.
  • Over 90% of BcACs are detected in the parotid gland.
  • The most important differential diagnosis is basal cell adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151548.001).
  • [ISSN] 1179-5557
  • [Journal-full-title] Clinical medicine insights. Pathology
  • [ISO-abbreviation] Clin Med Insights Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999998
  • [Keywords] NOTNLM ; basal cell adenocarcinoma / immunohistochemistry / post transplantation malignancy / salivary gland cancer
  •  go-up   go-down


45. Chen WL, Yang ZH, Huang ZQ, Chai Q, Zhang DM: Facial contour reconstruction after benign tumor ablation using reverse facial-submental artery deepithelialized submental island flaps. J Craniofac Surg; 2010 Jan;21(1):83-6
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent pleomorphic adenoma in the cheek and inferior temple was present in 3 patients, and recurrent basal cell adenoma was present in 1.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061969.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Li LJ, Li Y, Wen YM, Liu H, Zhao HW: Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol; 2008 Feb;44(2):187-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of salivary gland tumor cases in West China in past 50 years.
  • In our study, 3461 cases of salivary gland tumor treated between 1955 and 2002 at West China Stomatology Hospital of Sichuan University were retrospectively analyzed, and compared with the previous reports.
  • The findings are as follows: the average ages of salivary gland tumor patients were 41.38 years for the benign cases and 45.20 for the malignant ones; the male:female ratio was 0.
  • 99:1 in the benign cases and 1.34:1 in the malignant ones; primary tumors were mostly in the parotid gland, palate and submandibular gland in sequence.
  • Pleomorphic adenoma was the most frequent benign tumor followed by Warthin's tumor and basal cell adenoma, whereas mucoepidermoid carcinoma, adenoid cystic carcinoma and adenocarcinoma not otherwise specified were the most frequent malignant tumors.
  • The incidence of salivary gland tumors increased with age.
  • The parotid gland and palate were the most common locations of salivary gland tumors.
  • Pleomorphic adenoma and mucoepidermoid carcinoma were the most frequent benign and malignant tumors, respectively.
  • [MeSH-major] Adenoma, Pleomorphic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Salivary Gland Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oral Oncol. 2011 Sep;47(9):929-30
  • (PMID = 17418612.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Ihrler S, Schwarz S, Zengel P, Guntinas-Lichius O, Kirchner T, Weiler C: [Pleomorphic adenoma: pitfalls and clinicopathological forms of progression]. Pathologe; 2009 Nov;30(6):446-56
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleomorphic adenoma: pitfalls and clinicopathological forms of progression].
  • [Transliterated title] Das pleomorphe Adenom: Pitfalls in der Diagnostik und klinisch-pathologische Progressionsformen.
  • In the majority of cases the diagnosis of pleomorphic adenoma (PA) is straightforward.
  • In "monomorphic" types of PA problems may result: Epithelial-rich PA need to be distinguished from basal cell adenoma or canalicular adenoma.
  • The different progression steps of carcinoma ex pleomorphic adenoma (CEPA), starting with intraductal carcinoma, are highly relevant with respect to prognosis and therapy.
  • [MeSH-major] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic / pathology. Diagnosis, Differential. Disease Progression. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Reoperation. Salivary Ducts / pathology. Salivary Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2001 Sep;81(9):1289-97 [11555676.001]
  • [Cites] Virchows Arch. 2006 Aug;449(2):159-63 [16673121.001]
  • [Cites] Laryngoscope. 2001 Dec;111(12):2195-200 [11802025.001]
  • [Cites] Mod Pathol. 1996 Jun;9(6):652-7 [8782203.001]
  • [Cites] Pathologe. 2005 Sep;26(5):339-44 [16025256.001]
  • [Cites] Laryngoscope. 2004 Jan;114(1):158-63 [14710014.001]
  • [Cites] Poult Sci. 2000 Aug;79(8):1215-21 [10947195.001]
  • [Cites] J Pathol. 1998 Oct;186(2):178-85 [9924434.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Histopathology. 2005 Feb;46(2):144-52 [15693886.001]
  • [Cites] Histopathology. 2005 Jun;46(6):635-41 [15910594.001]
  • [Cites] Cancer. 1977 May;39(5):2209-30 [192443.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1048-55 [15920557.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Jul;35(7):608-12 [16540285.001]
  • [Cites] Head Neck. 2001 Sep;23(9):705-12 [11505478.001]
  • [Cites] HNO. 2008 Feb;56(2):231-8 [18214402.001]
  • [Cites] Laryngoscope. 1994 Oct;104(10):1231-4 [7934593.001]
  • [Cites] Histopathology. 2007 Sep;51(3):362-71 [17593217.001]
  • [Cites] HNO. 1977 Oct;25(10):337-48 [199562.001]
  • [Cites] Pathologe. 2005 Sep;26(5):345-52 [16049672.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):617-20 [9477091.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Head Neck. 2007 Sep;29(9):822-8 [17563905.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19844715.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


48. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Basal cell adenocarcinomas show strong immunoreactivity to cytokeratin 7 and variable myoepithelial staining with S100.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • Radiotherapy has been proposed for lesions in the minor salivary glands because of the higher likelihood of vascular and neural invasion and for those that are diffusely infiltrative.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Attlmayr B, Garrido C, Alderson DJ: Difficulty in establishing a diagnosis in an uncommon presentation of a minor salivary gland tumour. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difficulty in establishing a diagnosis in an uncommon presentation of a minor salivary gland tumour.
  • We report the case of a man presenting with a large, airway obstructing, minor salivary gland tumour arising from the right tonsillar base.
  • A firm diagnosis of malignancy could not be made histologically.
  • The differential diagnosis included polymorphous low-grade adenocarcinoma, basal cell adenoma and adenoid cystic carcinoma.
  • However, on balance, based on the clinical presentation, a diagnosis of malignancy was favoured and appropriate treatment was considered.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Airway Obstruction / etiology. Deglutition Disorders / etiology. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cooperative Behavior. Diagnosis, Differential. Endoscopy. Humans. Interdisciplinary Communication. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Palliative Care. Tongue / pathology. Tracheostomy

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Am J Surg. 1991 Oct;162(4):330-6 [1659242.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):443-54 [8655366.001]
  • [Cites] Cancer Treat Rev. 1996 Nov;22(6):395-423 [9134002.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Apr;87(4):485-92 [10225632.001]
  • [Cites] Ann Surg. 1956 Sep;144(3):366-83 [13363274.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • (PMID = 22798299.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3029651
  •  go-up   go-down


50. Olejniczak I, Kozłowski Z, Dabrowska K, Lukomski M: [Tumors of the parotid gland--management and results of surgical treatment]. Otolaryngol Pol; 2008;62(4):446-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumors of the parotid gland--management and results of surgical treatment].
  • INTRODUCTION: Tumors of the salivary glands are uncommon and represent 2-4% of head and neck neoplasms.
  • Most tumors originate in the parotid gland, from which 10 to 15% are found to be malignant.
  • MATERIAL AND METHODS: Retrospective analysis of the medical data of 138 patients with parotid gland tumors who where treated in our departament between 1997-2007 was done.
  • Benign tumors were found in 104 patients with the pleomorphic adenoma as the most common (53 cases).
  • The rest histological type were Whartin's tumor, myoepithelial and basal cell adenoma respectively.
  • The most frequent localization of the tumor after dividing the parotid gland into four parts was postero-inferior pole.
  • CONCLUSIONS: Frequency of tumors of the parotid gland, their histological types and methods of surgical treatment in our data support other studies.
  • Ultrasonography is the key procedure in the diagnosis of tumors of the parotid gland, qualification into surgical treatment and postoperative observation.
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / ultrasonography. Adult. Aged. Carcinoma, Mucoepidermoid / epidemiology. Carcinoma, Mucoepidermoid / ultrasonography. Female. Humans. Male. Middle Aged. Myoepithelioma / epidemiology. Myoepithelioma / ultrasonography. Poland. Retrospective Studies. Risk Factors. Salivary Gland Neoplasms / epidemiology. Salivary Gland Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837221.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


51. Mihashi H, Kawahara A, Kage M, Kojiro M, Nakashima T, Umeno H, Sakamoto K, Chiziwa H: Comparison of preoperative fine-needle aspiration cytology diagnosis and histopathological diagnosis of salivary gland tumors. Kurume Med J; 2006;53(1-2):23-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of preoperative fine-needle aspiration cytology diagnosis and histopathological diagnosis of salivary gland tumors.
  • We investigated 115 patients with salivary gland epithelial tumors who had undergone preoperative fine needle aspiration cytology (FNAC) of salivary glands and had been diagnosed by postoperative histopathological examination.
  • We compared the findings of preoperative FNAC with their histopathological types in salivary gland tumors, and discuss the results and problems.
  • The diagnostic accuracy, sensitivity, and specificity of preoperative FNAC of salivary glands were 98.2%, 88.2%, and 100%, respectively.
  • The rates of agreement in the diagnosis of pleomorphic adenoma, Warthin tumor, and basal cell adenoma were 96%, 92.9%, and 55.5%, respectively.
  • We realized again not only that the diagnostic accuracy of preoperative FNAC for salivary gland tumors was high, but also that it was a safe, easy-to-perform, clinically very useful diagnostic procedure.
  • [MeSH-major] Salivary Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043392.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


52. Ye WM, Zhu HG, Zheng JW, Wang XD, Zhao W, Zhong LP, Zhang ZY: Use of allogenic acellular dermal matrix in prevention of Frey's syndrome after parotidectomy. Br J Oral Maxillofac Surg; 2008 Dec;46(8):649-52
Genetic Alliance. consumer health - Frey's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: We studied a total of 168 patients with benign parotid gland tumours, including 89 patients with pleomorphic adenoma; 45 with Warthin tumour; 17 with basal cell adenoma; and 17 with miscellaneous tumours.
  • Salivary fistulas developed in 18 patients from the control group (17%), but in only 1 patient from the ADM group (2%).
  • [MeSH-major] Collagen. Oral Surgical Procedures / adverse effects. Parotid Gland / surgery. Skin, Artificial. Sweating, Gustatory / prevention & control
  • [MeSH-minor] Adenolymphoma / surgery. Adenoma / surgery. Adenoma, Pleomorphic / surgery. Adolescent. Adult. Aged. Humans. Middle Aged. Parotid Neoplasms / surgery. Salivary Gland Fistula / etiology. Salivary Gland Fistula / prevention & control. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18547692.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Alloderm; 9007-34-5 / Collagen
  •  go-up   go-down


53. Lü BJ, Zhu J, Gao L, Xie L, Xu JY, Lai MD: [Diagnostic accuracy and pitfalls in fine needle aspiration cytology of salivary glands: a study of 113 cases]. Zhonghua Bing Li Xue Za Zhi; 2005 Nov;34(11):706-10
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic accuracy and pitfalls in fine needle aspiration cytology of salivary glands: a study of 113 cases].
  • OBJECTIVE: To describe the fine needle aspiration cytology (FNAC) features of various salivary gland lesions and to analyze the respective diagnostic value and pitfalls.
  • METHODS: 113 FNAC specimens of salivary gland lesions were reviewed and correlated with clinical and histopathologic findings.
  • Cytologically, the distinction between cellular pleomorphic adenoma, adenoid cystic carcinoma and basal cell adenoma could be difficult due to their overlapping morphologic features.
  • CONCLUSIONS: FNAC is reliable in distinguishing benign and malignant salivary gland lesions.
  • A specific cytologic diagnosis is often possible.
  • On the other hand, due to the pitfalls in cytologic diagnosis of certain salivary gland tumors, tissue biopsy for histologic examination may be necessary.
  • [MeSH-major] Carcinoma, Mucoepidermoid / pathology. Carcinoma, Squamous Cell / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology
  • [MeSH-minor] Adenolymphoma / pathology. Adenoma / pathology. Adenoma, Pleomorphic / pathology. Adolescent. Adult. Aged. Biopsy, Fine-Needle. Carcinoma, Adenoid Cystic / pathology. Child. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Male. Middle Aged. Parotid Neoplasms / pathology. Retrospective Studies. Submandibular Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536312.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


54. Ostler DA, Prieto VG, Reed JA, Deavers MT, Lazar AJ, Ivan D: Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases. Mod Pathol; 2010 Apr;23(4):567-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases.
  • This study examines adipophilin expression in various sebaceous lesions and other cutaneous tumors with a clear cell histology that may mimic sebaceous differentiation.
  • A total of 117 cutaneous clear cell lesions including 16 sebaceous adenomas, 25 sebaceous carcinomas, 8 basal cell carcinomas, 12 squamous cell carcinomas, 6 xanthomas, 10 xanthelasmas, 10 xanthogranulomas, 4 balloon cell nevi, 5 trichilemmomas, 8 clear cell hidradenomas, and 13 metastatic renal cell carcinomas were examined using immunohistochemistry for the expression of adipophilin.
  • Adipophilin was expressed in 16 of 16 (100%) sebaceous adenomas, 23 of 25 (92%) sebaceous carcinomas, 10 of 10 (100%) xanthelasmas, 9 of 10 (90%) xanthogranulomas, 6 of 6 (100%) xanthomas, and 9 of 13 (62.5%) metastatic renal cell carcinomas.
  • Adipophilin expression was not seen in any of the other lesions with clear cell histology, basal cell carcinomas, or squamous cell carcinomas, including cases that had focal clear cell differentiation.
  • Adipophilin can be valuable in an immunohistochemical panel when evaluating cutaneous lesions with clear cell histology as it identifies intracytoplasmic lipid vesicles in sebaceous and xanthomatous lesions.
  • In periocular lesions, it is effective in helping to exclude basal cell carcinoma and squamous cell carcinoma when sebaceous carcinoma is under consideration.
  • Adipophilin expression is not as useful for the differential diagnosis that includes metastatic renal cell carcinoma, a rare but important, diagnostic differential.
  • [MeSH-major] Biomarkers, Tumor / analysis. Peptides / metabolism. Sebaceous Gland Neoplasms / metabolism. Sebaceous Gland Neoplasms / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118912.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Peptides; 0 / perilipin 2
  •  go-up   go-down


55. Gürbüz Y, Yildiz K, Aydin O, Almaç A: Immunophenotypical profiles of salivary gland tumours: a new evidence for their histogenetic origin. Pathologica; 2006 Apr;98(2):147-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypical profiles of salivary gland tumours: a new evidence for their histogenetic origin.
  • The histogenetic origin of salivary gland tumours is not clear.
  • In normal tissues smooth muscle actin (SMA) is expressed in myoepithelial cells, CK14 immunoreactivity is seen in myoepithelial and basal cells and CK10 in keratinized squamous epithelium.
  • In this study, we examine the immunophenotypic properties of salivary gland tumours in order to obtain further insight into their histogenesis.
  • 30 cases of salivary gland tumours (18 pleomorphic adenomas, 8 Warthin's tumours, 2 basal cell adenomas, 2 acinic cell carcinomas) were included in our study.
  • CK14 was found in all tumours except acinic cell carcinomas (p < 0.0001).
  • In conclusion, pleomorphic adenomas and basal cells adenomas originate from stem cells.
  • [MeSH-major] Actins / analysis. Keratins / analysis. Neoplasm Proteins / analysis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenolymphoma / chemistry. Adenolymphoma / pathology. Adenoma / chemistry. Adenoma / pathology. Adenoma, Pleomorphic / chemistry. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell / chemistry. Carcinoma, Acinar Cell / pathology. Humans. Immunophenotyping. Organ Specificity. Protein Isoforms / analysis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929788.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Actins; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 68238-35-7 / Keratins
  •  go-up   go-down


56. Gerdes MJ, Yuspa SH: The contribution of epidermal stem cells to skin cancer. Stem Cell Rev; 2005;1(3):225-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of transgenic and knockout gene technologies with mice is unraveling some of the specific genes regulating fate determination in stem cells other than squamous lineage, including basal cell carcinoma and sebaceous adenomas.
  • The following review examines the evidence for the stem cell origin of epidermal tumors and the contribution of some specific gene families toward stem cell fate decisions during epidermal tumor progression.
  • [MeSH-major] Adenocarcinoma, Sebaceous / genetics. Carcinoma, Basal Cell / genetics. Epidermis. Epigenesis, Genetic. Neoplastic Stem Cells. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12483-8 [12221288.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):114-7 [10973262.001]
  • [Cites] Development. 2004 Apr;131(8):1787-99 [15084463.001]
  • [Cites] Dev Biol. 1999 Jan 1;205(1):1-9 [9882493.001]
  • [Cites] Cancer Res. 1988 Nov 15;48(22):6285-90 [2460219.001]
  • [Cites] EMBO J. 1997 May 1;16(9):2365-75 [9171350.001]
  • [Cites] Exp Biol Med (Maywood). 2001 Sep;226(8):753-7 [11520941.001]
  • [Cites] Curr Biol. 2001 Apr 17;11(8):558-68 [11369200.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):79-90 [15051492.001]
  • [Cites] J Invest Dermatol. 1999 Apr;112(4):470-5 [10201531.001]
  • [Cites] Nat Genet. 1999 Apr;21(4):410-3 [10192393.001]
  • [Cites] J Invest Dermatol. 2003 Apr;120(4):501-11 [12648211.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Cell. 2001 Jan 26;104(2):233-45 [11207364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7822-6 [8052666.001]
  • [Cites] Stem Cells. 2002;20(1):21-31 [11796919.001]
  • [Cites] J Invest Dermatol. 1994 Nov;103(5 Suppl):90S-95S [7963691.001]
  • [Cites] Oncogene. 2001 Aug 30;20(38):5341-9 [11536046.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):2961-4 [8319202.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4803-10 [8402665.001]
  • [Cites] J Dermatol. 2004 May;31(5):368-75 [15187303.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):411-7 [15024388.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4742-7 [10758156.001]
  • [Cites] J Invest Dermatol. 1993 Oct;101(4):591-4 [8409528.001]
  • [Cites] Science. 2004 Jan 16;303(5656):359-63 [14671312.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10960-5 [11005869.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11873-80 [12917489.001]
  • [Cites] Cell Tissue Res. 1985;242(3):551-6 [2416451.001]
  • [Cites] Mol Carcinog. 1997 Sep;20(1):151-8 [9328446.001]
  • [Cites] Cell. 2004 Sep 3;118(5):635-48 [15339667.001]
  • [Cites] J Invest Dermatol. 1996 Apr;106(4):759-65 [8618017.001]
  • [Cites] Cell. 1993 May 21;73(4):713-24 [8500165.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Hum Mol Genet. 2003 Nov 15;12(22):2931-40 [14506134.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] EMBO J. 2003 Jun 16;22(12):2981-91 [12805213.001]
  • [Cites] Cancer Res. 1986 Jun;46(6):3061-6 [3698024.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Cell. 1998 Nov 25;95(5):605-14 [9845363.001]
  • [Cites] J Cell Biol. 2000 Sep 4;150(5):1149-60 [10974002.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2038-44 [10570429.001]
  • [Cites] J Invest Dermatol. 2001 May;116(5):739-42 [11348463.001]
  • [Cites] J Invest Dermatol. 2000 Nov;115(5):788-94 [11069615.001]
  • [Cites] J Cell Sci. 1987 Oct;88 ( Pt 3):305-12 [3129440.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1329-37 [2364430.001]
  • [Cites] J Cell Sci. 1978 Feb;29:249-69 [627606.001]
  • [Cites] Mol Cell Biol. 2004 Feb;24(4):1608-13 [14749376.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2619-30 [11387197.001]
  • [Cites] Carcinogenesis. 1991 Jun;12(6):1119-24 [2044193.001]
  • [Cites] EMBO J. 2001 Mar 15;20(6):1215-22 [11250888.001]
  • [Cites] Mol Carcinog. 1993;7(2):99-110 [7681293.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3436-43 [9270010.001]
  • [Cites] J Invest Dermatol. 1999 Oct;113(4):595-9 [10504446.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):3990-4003 [10921880.001]
  • [Cites] Differentiation. 2004 Oct;72(8):371-80 [15606496.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):226-9 [10667563.001]
  • [Cites] J Invest Dermatol. 1998 Dec;111(6):1045-52 [9856815.001]
  • [Cites] Nature. 1983 Jul 7-13;304(5921):69-71 [6408484.001]
  • [Cites] Int J Cancer. 1987 Jun 15;39(6):778-84 [3294611.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] Cell. 2000 Aug 18;102(4):451-61 [10966107.001]
  • [Cites] Dev Biol. 2003 Nov 15;263(2):203-15 [14597196.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):963-8 [14708593.001]
  • [Cites] J Cell Sci. 1996 May;109 ( Pt 5):1017-28 [8743949.001]
  • [Cites] Cell. 2001 May 18;105(4):533-45 [11371349.001]
  • [Cites] Cell Biol Int. 2004;28(7):523-9 [15261160.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10 (7):757-62 [11257109.001]
  • [Cites] Curr Biol. 1998 Apr 23;8(9):516-24 [9560338.001]
  • [Cites] Cancer Detect Prev. 1996;20(1):20-30 [8907200.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):165-8 [11381265.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(4):1436-47 [10648628.001]
  • [Cites] Pathol Res Pract. 1994 Oct;190(9-10):950-4 [7899145.001]
  • [Cites] Development. 2002 Jan;129(1):95-109 [11782404.001]
  • [Cites] J Cutan Pathol. 1994 Dec;21(6):500-6 [7699116.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):1095-103 [14708612.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61 [11248048.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2173-8 [14633591.001]
  • [Cites] J Cell Sci. 1998 Nov;111 ( Pt 21):3179-88 [9763512.001]
  • [Cites] Oncogene. 1996 Feb 15;12(4):765-73 [8632898.001]
  • [Cites] J Invest Dermatol. 1997 Jan;108(1):113-7 [8980299.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3779-82 [6430553.001]
  • [Cites] J Natl Cancer Inst. 1986 Jan;76(1):151-8 [3455737.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1791-803 [9137102.001]
  • [Cites] Mol Cell. 1999 May;3(5):565-77 [10360173.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:28-33 [10466758.001]
  • [Cites] Trends Mol Med. 2004 Dec;10(12):577-80 [15567325.001]
  • [Cites] Cell. 1990 Aug 24;62(4):697-708 [1696852.001]
  • [Cites] Acta Derm Venereol. 1994 Mar;74(2):101-5 [7911612.001]
  • (PMID = 17142859.001).
  • [ISSN] 1550-8943
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


57. Tian C, Ye F, Wang L, Deng Y, Dong Y, Wang X, Xu T, Lei T, Wang X: Nitric oxide inhibits ghrelin-induced cell proliferation and ERK1/2 activation in GH3 cells. Endocrine; 2010 Dec;38(3):412-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide inhibits ghrelin-induced cell proliferation and ERK1/2 activation in GH3 cells.
  • Ghrelin stimulates growth hormone release and cell proliferation, which strongly supports a significant role for this peptide in the control of growth hormone-releasing adenomas function and growth.
  • Nitric oxide can influence the stimulatory effects of ghrelin on growth hormone secretion in growth hormone-releasing adenomas.
  • However, the effect of nitric oxide (NO) on ghrelin-induced cell proliferation and the mechanism of this effect in the adenoma were not clarified.
  • A NO donor, S-nitroso-N-acetylpenicillamine (SNAP), blunted basal, and ghrelin-induced cell proliferation.
  • Together, this study indicates that NO inhibited ghrelin-induced cell proliferation by blocking ERK1/2 activation in GH3 cells.
  • [MeSH-major] Cell Proliferation / drug effects. Ghrelin / pharmacology. Mitogen-Activated Protein Kinase 3 / metabolism. Nitric Oxide / pharmacology. Somatotrophs / drug effects
  • [MeSH-minor] Animals. Cell Line. Down-Regulation / drug effects. Enzyme Activation / drug effects. Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 1 / metabolism. Protein Kinase Inhibitors / pharmacology. Rats

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosci Lett. 2008 Jul 4;439(1):94-9 [18511197.001]
  • [Cites] Neurochem Res. 2007 Apr-May;32(4-5):681-94 [17043768.001]
  • [Cites] Neuroendocrinology. 2004;80(2):83-91 [15475661.001]
  • [Cites] Endocr J. 1999 Dec;46(6):779-85 [10724353.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):170-4 [7529411.001]
  • [Cites] Neuropeptides. 1996 Dec;30(6):528-32 [9004249.001]
  • [Cites] Nitric Oxide. 2009 Sep;21(2):92-103 [19602444.001]
  • [Cites] Pharmacol Rev. 2005 Dec;57(4):541-6 [16382107.001]
  • [Cites] Nature. 1999 Dec 9;402(6762):656-60 [10604470.001]
  • [Cites] J Neuroendocrinol. 2008 Mar;20(3):406-12 [18208548.001]
  • [Cites] Eur J Endocrinol. 2004 Aug;151(2):233-40 [15296479.001]
  • [Cites] J Neurochem. 2003 Mar;84(6):1367-77 [12614337.001]
  • [Cites] Nature. 1990 Oct 25;347(6295):768-70 [1700301.001]
  • [Cites] Tissue Cell. 2009 Apr;41(2):133-40 [19019400.001]
  • [Cites] Sci STKE. 2000 Jul 11;2000(40):re1 [11752597.001]
  • [Cites] Neuroendocrinology. 1997 Dec;66(6):426-31 [9430448.001]
  • [Cites] Mol Vis. 2008 May 28;14:983-91 [18523663.001]
  • [Cites] Endocrine. 2009 Feb;35(1):112-7 [18953675.001]
  • [Cites] Neuroendocrinology. 1996 Aug;64(2):146-52 [8857609.001]
  • [Cites] Mol Endocrinol. 2004 Sep;18(9):2291-301 [15178745.001]
  • [Cites] Neuroendocrinology. 2001 Oct;74(4):213-9 [11598377.001]
  • [Cites] Science. 1996 Aug 16;273(5277):974-7 [8688086.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2004 Nov 22;42(22):1349-52 [15634400.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):1010-22 [11376118.001]
  • [Cites] Inflamm Res. 2000 Oct;49(10):541-7 [11089907.001]
  • [Cites] Endocrine. 2005 Nov;28(2):209-16 [16388095.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Jan;290(1):C233-43 [16207796.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5667-74 [11724768.001]
  • [Cites] Endocr Rev. 2004 Jun;25(3):426-57 [15180951.001]
  • [Cites] Free Radic Biol Med. 2008 Jul 1;45(1):18-31 [18439435.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1300-8 [11889202.001]
  • (PMID = 20972719.001).
  • [ISSN] 1559-0100
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Protein Kinase Inhibitors; 31C4KY9ESH / Nitric Oxide; EC 2.7.11.24 / Mapk1 protein, rat; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


58. Honeycutt KA, Waikel RL, Koster MI, Wang XJ, Roop DR: The effect of c-myc on stem cell fate influences skin tumor phenotype. Mol Carcinog; 2010 Apr;49(4):315-9
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of c-myc on stem cell fate influences skin tumor phenotype.
  • Nonmelanoma skin cancers (NMSCs) consist of a variety of tumor types including basal cell carcinoma, squamous cell carcinoma, a variety of hair follicle tumors, and sebaceous gland tumors.
  • Our goal in the current study was to determine if alterations in the commitment of multipotent stem cells to different cell fates would influence tumor phenotype.
  • To this end, we exposed K14.MYC2 mice to a chemical carcinogenesis protocol and discovered that these mice were predisposed to develop sebaceous adenomas.
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma, Sebaceous / pathology. Animals. Carcinogens / toxicity. Cell Differentiation / genetics. Cell Lineage / genetics. Crosses, Genetic. Female. Heterozygote. Male. Mice. Mice, Inbred ICR. Mice, Inbred Strains. Mice, Transgenic. Multipotent Stem Cells / pathology. Papilloma / pathology. Phenotype. Sebaceous Gland Neoplasms / pathology. Tetradecanoylphorbol Acetate / pharmacology. Transgenes

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146250.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR47898; United States / NCI NIH HHS / CA / CA09197; United States / NCI NIH HHS / CA / CA105491; United States / NCI NIH HHS / CA / CA52607; United States / NCI NIH HHS / CA / CA79998
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Proto-Oncogene Proteins c-myc; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


59. Driemel O, Maier H, Kraft K, Haase S, Hemmer J: Flow cytometric DNA ploidy in salivary gland tumours. Oncol Rep; 2005 Jan;13(1):161-5
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric DNA ploidy in salivary gland tumours.
  • This study on 279 tumours of the salivary glands was conducted to analyse whether the assessment of DNA ploidy by flow cytometry may assist histopathology in discriminating benign from malignant types of tumours.
  • The group of benign tumours included 164 pleomorphic adenomas, 51 Warthin's tumours, 7 basal cell adenomas, 2 lipomas as well as 5 other different tumours.
  • The malignant tumours consisted of 18 adenoid cystic adenomas, 10 mucoepidermoid carcinomas, 5 acinic cell carcinomas, 5 carcinoma in pleomorphic adenoma as well as of 12 other malignancies belonging to 7 different tumour entities.
  • Twelve of 50 malignant salivary gland tumours were aneuploid.
  • In three cases which initially were taken for pleomorphic adenomas by routine histological examination, aneuploid cell populations exposed by DNA flow cytometric analysis gave rise to a closer inspection of the suspect lesions.
  • Examination of consecutive slides actually revealed small assemblies of carcinoma cells that required a final diagnosis as non-invasive carcinoma in pleomorphic adenoma.
  • The most obvious value of DNA flow cytometry in salivary gland tumours is thus its contribution to assist histopathology in identifying potentially malignant lesions.
  • [MeSH-major] DNA, Neoplasm / analysis. Flow Cytometry. Ploidies. Salivary Gland Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Salivary Glands / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583819.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


60. Yerli H, Aydin E, Haberal N, Harman A, Kaskati T, Alibek S: Diagnosing common parotid tumours with magnetic resonance imaging including diffusion-weighted imaging vs fine-needle aspiration cytology: a comparative study. Dentomaxillofac Radiol; 2010 Sep;39(6):349-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: masses comprised eight Warthin tumours, eight adenomas (six pleomorphic adenomas, two basal cell adenomas), five carcinomas, two lipomas, one haemagioma and one benign lymphadenopathy.
  • [MeSH-major] Adenolymphoma / pathology. Adenoma / pathology. Biopsy, Fine-Needle. Carcinoma / pathology. Diffusion Magnetic Resonance Imaging. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1999 Nov;35(5):432-8 [10583558.001]
  • [Cites] Radiology. 2000 Jul;216(1):19-29 [10887223.001]
  • [Cites] Radiology. 2001 Sep;220(3):621-30 [11526259.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1989-92 [11801984.001]
  • [Cites] AJR Am J Roentgenol. 2002 Apr;178(4):959-65 [11906883.001]
  • [Cites] Clin Radiol. 2002 Aug;57(8):692-701 [12169280.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Aug;25(7):1256-62 [15313720.001]
  • [Cites] Radiology. 1989 Dec;173(3):823-6 [2813793.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Mar;17(3):555-9 [8881252.001]
  • [Cites] Head Neck. 1999 Jan;21(1):43-51 [9890350.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 May;26(5):1201-6 [15891184.001]
  • [Cites] Ann Acad Med Singapore. 2006 Apr;35(4):242-8 [16710494.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Jan;28(1):116-21 [17213436.001]
  • [Cites] Acad Radiol. 2007 Jun;14(6):701-10 [17502260.001]
  • [Cites] Acta Radiol. 2007 Nov;48(9):980-7 [17957512.001]
  • [Cites] AJNR Am J Neuroradiol. 2009 Mar;30(3):591-6 [19131405.001]
  • (PMID = 20729184.001).
  • [ISSN] 0250-832X
  • [Journal-full-title] Dento maxillo facial radiology
  • [ISO-abbreviation] Dentomaxillofac Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3520240
  •  go-up   go-down


61. Zhang X: Simultaneous exposure to dietary acrylamide and corn oil developed carcinogenesis through cell proliferation and inhibition of apoptosis by regulating p53-mediated mitochondria-dependent signaling pathway. Toxicol Ind Health; 2009 Mar;25(2):101-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous exposure to dietary acrylamide and corn oil developed carcinogenesis through cell proliferation and inhibition of apoptosis by regulating p53-mediated mitochondria-dependent signaling pathway.
  • Colonic aberrant crypt foci (ACF) and tumors, including adenomas and carcinomas, were examined at 12, 24, 36, 48 week post ACR-exposure.
  • Colonic apoptosis and cell proliferation, expression of Wild type (wt) p53, Bcl-2, Bax and caspase-3, were detected at 48 week post ACR-exposure.
  • Apoptosis was decreased and cell proliferation was increased in colonic mucosa in ACR-treated rats on dietary corn oil compared to vehicle rats on basal diet (P < 0.05).
  • [MeSH-major] Acrylamide / toxicity. Apoptosis / drug effects. Cell Proliferation / drug effects. Corn Oil / administration & dosage. Gene Expression Regulation, Neoplastic / drug effects. Precancerous Conditions / chemically induced. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adenoma / chemically induced. Adenoma / pathology. Animals. Carcinogenicity Tests. Cocarcinogenesis. Colon / drug effects. Colon / pathology. Colonic Neoplasms / chemically induced. Colonic Neoplasms / pathology. Diet. Injections, Intraperitoneal. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Male. Mitochondria / drug effects. Mitochondria / metabolism. Rats. Rats, Sprague-Dawley. Signal Transduction / drug effects

  • Hazardous Substances Data Bank. ACRYLAMIDE .
  • Hazardous Substances Data Bank. Corn oil .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458132.001).
  • [ISSN] 0748-2337
  • [Journal-full-title] Toxicology and industrial health
  • [ISO-abbreviation] Toxicol Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 20R035KLCI / Acrylamide; 8001-30-7 / Corn Oil
  •  go-up   go-down


62. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM: Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem; 2006 May 12;281(19):13548-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
  • Inhibitors of histone deacetylases (HDACs) induce growth arrest, differentiation, and apoptosis of colon cancer cell lines in vitro and have demonstrated anti-cancer efficacy in clinical trials.
  • Here we demonstrate increased protein expression of HDAC3 in human colon tumors and in duodenal adenomas from Apc1638(N/+) mice.
  • Silencing of HDAC3 expression in colon cancer cell lines resulted in growth inhibition, a decrease in cell survival, and increased apoptosis.
  • HDAC3 silencing also selectively induced expression of alkaline phosphatase, a marker of colon cell maturation.
  • Concurrent with its effect on cell growth, overexpression of HDAC3 and other Class I HDACs inhibited basal and butyrate-induced p21 transcription in a Sp1/Sp3-dependent manner, whereas silencing of HDAC3 stimulated p21 promoter activity and expression.
  • These findings identify HDAC3 as a gene deregulated in human colon cancer and as a novel regulator of colon cell maturation and p21 expression.
  • [MeSH-minor] Apoptosis. Caco-2 Cells. Cell Differentiation. Cell Proliferation. Colon / cytology. Colonic Neoplasms. Down-Regulation. Gene Expression Regulation, Enzymologic. Gene Silencing. HCT116 Cells. Histone Deacetylase Inhibitors. Humans. Time Factors. Up-Regulation

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533812.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA100823-03; United States / NCI NIH HHS / CA / CA88104-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Histone Deacetylase Inhibitors; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


63. Durán CE, Torregrosa JV, Canalejo A, Almadén Y, Campistol JM, Rodríguez Portillo M: [In vitro dynamics of parathyroid hormone secretion regulated by calcium and effects on the cell cycle: parathyroid hyperplasia versus adenoma]. Nefrologia; 2010;30(4):413-9
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [In vitro dynamics of parathyroid hormone secretion regulated by calcium and effects on the cell cycle: parathyroid hyperplasia versus adenoma].
  • [Transliterated title] Dinámica in vitro de la secreción de hormona paratiroidea regulada por calcio y efecto sobre el ciclo celular: adenoma frente a hiperplasia paratiroidea.
  • AIM: To compare the dynamics of calcium-regulated PTH secretion in vitro from adenomatous versus hyperplastic glands and to investigate the relationship between the parathyroid cell cycle and the calcium-regulated PTH secretion in these glands.
  • For the parathyroid cell cycle studies, parathyroid cells were isolated without the use of enzymes and cell cycle was analyzed using the method described by Vindelov.
  • In hyperplastic parathyroid glands but not in parathyroid adenomas there was a significant correlation between the percentage of cells in G0/G1 phase with the set point (r = 0.914; P < 0.005) and the basal serum Ca (r = 0.862; P < 0.02).
  • CONCLUSIONS: The control of the extracellular calcium-PTH release in vitro is less sensitive in parathyroid adenomas than hyperplasic parathyroid glands.
  • In parathyroid hyperplasia the cell proliferation may be regulated by the extracellular calcium concentration (higher calcemia less proliferation).
  • [MeSH-major] Adenoma / secretion. Calcium / physiology. Cell Cycle / physiology. Parathyroid Glands / pathology. Parathyroid Glands / secretion. Parathyroid Hormone / secretion. Parathyroid Neoplasms / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651882.001).
  • [ISSN] 0211-6995
  • [Journal-full-title] Nefrología : publicación oficial de la Sociedad Española Nefrologia
  • [ISO-abbreviation] Nefrologia
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Parathyroid Hormone; SY7Q814VUP / Calcium
  •  go-up   go-down


64. Higgins HJ, Voutsalath M, Holland JM: Muir-torre syndrome: a case report. J Clin Aesthet Dermatol; 2009 Aug;2(8):30-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Characteristic sebaceous neoplasms include sebaceous adenoma, sebaceous carcinoma, sebaceoma, and keratoacanthoma with sebaceous differentiation.
  • The clinical and histological features of a patient with Muir-Torre syndrome who had two sebaceous adenomas, multiple basal cell carcinomas, and frontal bossing in association with colon cancer are presented in this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1968 Nov;98(5):549-51 [5684233.001]
  • [Cites] Br J Surg. 1967 Mar;54(3):191-5 [6020987.001]
  • [Cites] J Am Acad Dermatol. 1995 Jul;33(1):90-104 [7601953.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):79-89 [7712655.001]
  • [Cites] Cutis. 2005 Mar;75(3):149-55 [15839358.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):980-7 [16321766.001]
  • [Cites] Am J Dermatopathol. 2006 Feb;28(1):56-9 [16456327.001]
  • [Cites] World J Surg Oncol. 2006;4:8 [16466577.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):1039-42 [16924054.001]
  • [Cites] Gastrointest Endosc. 2008 Sep;68(3):608-10 [18308310.001]
  • [Cites] Cutis. 2008 Oct;82(4):252-6 [19055168.001]
  • [Cites] Dermatol Ther. 2008 Nov-Dec;21(6):459-66 [19076624.001]
  • (PMID = 20729952.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2923964
  •  go-up   go-down


65. Jung YH, Hah JH, Sung MW, Kim KH: Parotidotomy approach for a midcheek mass: a new surgical strategy. Laryngoscope; 2010 Mar;120(3):495-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: To report the feasibility and the results of a new surgical strategy for midcheek masses we called the parotidotomy approach.
  • The parotid gland was fully bisected along the course of the zygomatic and buccal branches of the facial nerve to provide access to the midcheek mass.
  • The bisected parotid gland was repositioned after mass excision.
  • The parotidotomy approach was accomplished in two cases with a malignant tumor (one acinic cell carcinoma, one low-grade mucoepidermoid carcinoma), four with a benign tumor (two pleomorphic adenoma, one basal cell adenoma, one facial nerve schwannoma), and in one case with a chronic inflammatory lesion (chronic sialadenitis).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058313.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Quentien MH, Barlier A, Franc JL, Pellegrini I, Brue T, Enjalbert A: Pituitary transcription factors: from congenital deficiencies to gene therapy. J Neuroendocrinol; 2006 Sep;18(9):633-42
MedlinePlus Health Information. consumer health - Pituitary Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies on Snell and Jackson mice known to have growth hormone, prolactin and thyroid-stimulating hormone deficiencies involving the hypoplastic pituitary gland have led to identifying alterations of the pituitary specific POU homeodomain Pit-1 transcription factor gene.
  • Terminal differentiation of lactotroph cells and direct regulation of the prolactin gene both require interactions between Pit-1 and cell type specific partners, including panpituitary transcriptional regulators such as Pitx1 and Pitx2.
  • Synergistic activation of the prolactin promoter by Pitx factors and Pit-1 is involved not only in basal condition, but also in responsiveness to forskolin, thyrotrophin-releasing-hormone and epidermal growth factor.
  • The effects of Pit-1 are not restricted to hormone gene regulation because this factor also contributes to cell division and protects the cell from programmed cell death.
  • Lentiviral vectors expressing a Pit-1 dominant negative mutant induced time- and dose-dependent cell death in somatotroph and lactotroph adenomas in vitro.
  • Gene transfer by lentiviral vectors should provide a promising step towards developing an efficient specific therapeutic approach by which a gene therapy programme for treating human pituitary adenomas could be based.
  • [MeSH-major] Gene Expression Regulation / physiology. Genetic Therapy. Pituitary Diseases / genetics. Pituitary Gland, Anterior / metabolism. Pituitary Hormones / metabolism. Transcription Factor Pit-1 / metabolism

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879162.001).
  • [ISSN] 0953-8194
  • [Journal-full-title] Journal of neuroendocrinology
  • [ISO-abbreviation] J. Neuroendocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Pituitary Hormones; 0 / T-Box Domain Proteins; 0 / TBX19 protein, human; 0 / Transcription Factor Pit-1; 0 / Transcription Factors; 184787-43-7 / homeobox protein PITX2; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone
  • [Number-of-references] 98
  •  go-up   go-down


67. Pons Vicente O, Almendros Marqués N, Berini Aytés L, Gay Escoda C: Minor salivary gland tumors: A clinicopathological study of 18 cases. Med Oral Patol Oral Cir Bucal; 2008 Sep;13(9):E582-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minor salivary gland tumors: A clinicopathological study of 18 cases.
  • INTRODUCTION: Minor salivary gland tumors (MSGTs) are infrequent, representing 10-15% of all salivary neoplasms.
  • The histopathological diagnoses of our MSGTs comprised 10 pleomorphic adenomas (55.3%), 2 cystadenomas (11.1%), 1 myoepithelioma (5.6%), 1 sialadenoma papilliferum (5.6%), 1 basal cell adenoma (5.6%), 1 Warthin's tumor (5.6%), 1 canalicular adenoma (5.6%), and 1 low-grade polymorphic adenocarcinoma (5.6%).
  • Six percent of all benign minor salivary gland tumors are considered to relapse, versus 65% of all malignant lesions.
  • [MeSH-major] Salivary Gland Neoplasms / pathology. Salivary Glands, Minor

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758404.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 30
  •  go-up   go-down


68. Habermann CR, Arndt C, Graessner J, Diestel L, Petersen KU, Reitmeier F, Ussmueller JO, Adam G, Jaehne M: Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible? AJNR Am J Neuroradiol; 2009 Mar;30(3):591-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible?
  • BACKGROUND AND PURPOSE: Our aim was to determine the value of echo-planar diffusion-weighted MR imaging (epiDWI) in differentiating various types of primary parotid gland tumors.
  • MATERIALS AND METHODS: One hundred forty-nine consecutive patients with suspected tumors of the parotid gland were examined with an epiDWI sequence by using a 1.5T unit.
  • Histologic diagnosis was obtained in every patient.
  • RESULTS: In 136 patients, a primary parotid gland tumor was confirmed by histology.
  • ADC values of pleomorphic adenomas were significantly higher than those of all other entities, except for myoepithelial adenomas (P = .054).
  • ADC values of Warthin tumors were different from those of myoepithelial adenomas, lipomas, and salivary duct carcinomas (P < .001, 0.013, and .037, respectively).
  • Mucoepidermoid carcinomas, acinic cell carcinomas, and basal cell adenocarcinomas were not differentiable from Warthin tumors (P = .094, .396, and .604, respectively).
  • CONCLUSION: epiDWI has the potential to differentiate pleomorphic adenoma and myoepithelial adenomas from all other examined entities.
  • Therefore, further studies combining DWI, morphologic criteria, and probably other MR imaging techniques seem warranted.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Echo-Planar Imaging. Myoepithelioma / pathology. Parotid Gland / pathology
  • [MeSH-minor] Adenolymphoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Female. Humans. Lipoma / pathology. Male. Middle Aged. Prospective Studies. Salivary Gland Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131405.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Kazakov DV, Sima R, Vanecek T, Kutzner H, Palmedo G, Kacerovska D, Grossmann P, Michal M: Mutations in exon 3 of the CTNNB1 gene (beta-catenin gene) in cutaneous adnexal tumors. Am J Dermatopathol; 2009 May;31(3):248-55
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA was extracted from 86 lesions including 17 proliferating tricholemmal and trichilemmal tumors, 15 trichoblastomas, 7 trichoadenomas, 4 pilomatricomas, 1 pilomatrical carcinoma, 4 basal cell carcinomas (BCCs) with shadow cells, 2 trichofolliculomas, 3 BCCs with sebaceous differentiation, 9 sebaceous adenomas, 6 sebaceomas, 14 sebaceous carcinomas (both ocular and extraocular forms), 2 gigantic horns, and 2 apocrine mixed tumors with shadow cells and subjected to polymerase chain reaction with newly designed primers encompassing glycogen synthase kinase-3beta phosphorylation sites of the CTNNB1 gene.
  • These included 5 different point mutations, 3 of them identified in 2 different tumors: S23N (cribriform trichoblastoma), D32Y (pilomatricoma and craniopharyngioma), G34R (pilomatrical carcinoma and craniopharyngioma), S37F (2 BCCs with shadow cell differentiation), and G34V (craniopharyngioma).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Base Sequence. Cell Differentiation. Child. Child, Preschool. Craniopharyngioma / genetics. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Molecular Sequence Data. Pituitary Neoplasms / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384065.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / beta Catenin
  •  go-up   go-down


70. Kamei Y, Kito K, Takeuchi T, Imai Y, Murase R, Ueda N, Kobayashi N, Abe Y: Human scribble accumulates in colorectal neoplasia in association with an altered distribution of beta-catenin. Hum Pathol; 2007 Aug;38(8):1273-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Drosophila, genetic studies identified 3 neoplastic tumor suppressor genes (nTSGs), and a loss of nTSGs has been shown to result in a disruption of apical-basal polarity and neoplastic growth in epithelial cells.
  • In 50 cases of colorectal adenomas and adenocarcinomas, the accumulation of hScrib protein was commonly observed in comparison with the adjacent normal epithelia.
  • Like beta-catenin, the intense immunoreactivity of hScrib was often observed in small adenomas, thus, suggesting that hScrib could be involved in an early step of colon carcinogenesis.
  • In an immunofluorescence analysis on cultured cell lines, the loss of membranous staining of hScrib was observed according to the cytoplasmic translocation of beta-catenin.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / pathology. Membrane Proteins / metabolism. Tumor Suppressor Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509663.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Membrane Proteins; 0 / SCRIB protein, human; 0 / Tumor Suppressor Proteins; 0 / beta Catenin
  •  go-up   go-down


71. Candolfi M, Jaita G, Pisera D, Ferrari L, Barcia C, Liu C, Yu J, Liu G, Castro MG, Seilicovich A: Adenoviral vectors encoding tumor necrosis factor-alpha and FasL induce apoptosis of normal and tumoral anterior pituitary cells. J Endocrinol; 2006 Jun;189(3):681-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although we observed basal expression of TNF-alpha and FasL in control cultures of anterior pituitary cells, fluorescence-activated cell sorting (FACS) cell cycle analysis showed that the overexpression of TNF-alpha or FasL increases the percentage of hypodiploid lactotropes and somatotropes.
  • We detected strong immunoreactivity for TNFR1 and Fas in the somatolactotrope cell line GH3.
  • TNF-alpha or FasL immunoreactivity was not observed in the corticotrope cell line AtT20.
  • The expression of beta-Gal was detected in all these cultures but did not affect cell viability.
  • Therefore, overexpression of proapoptotic factors could be a useful tool in the therapy of pituitary adenomas.
  • [MeSH-major] Adenoviridae / genetics. Genetic Vectors / administration & dosage. Membrane Glycoproteins / genetics. Pituitary Gland, Anterior / cytology. Pituitary Neoplasms / pathology. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factors / genetics
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Fas Ligand Protein. Female. Flow Cytometry. Gene Expression. Immunohistochemistry / methods. Rats. Rats, Sprague-Dawley. Rats, Wistar

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731798.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / 1R03 TW006273-01; United States / NINDS NIH HHS / NS / 1R21 NS047298-01; United States / NINDS NIH HHS / NS / NS 42893-01; United States / NINDS NIH HHS / NS / U54 NS045309-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Tnfsf6 protein, rat; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Necrosis Factors
  •  go-up   go-down


72. Hara H, Oyama T, Suda K: New criterial for cytologic diagnosis of adenoid cystic carcinoma. Acta Cytol; 2005 Jan-Feb;49(1):43-50
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New criterial for cytologic diagnosis of adenoid cystic carcinoma.
  • STUDY DESIGN: The usefulness of 17 items for a cytologically definitive diagnosis of ADCC was examined.
  • The frequency (- - +++) of the 17 items in 18 cases of ADCC and 10 non-ADCC cases (pleomorphic adenoma, basal cell adenoma, myoepithelioma and epithelial-myoepithelial carcinoma) that displayed mimicking cytology was examined cytologically.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenoma / diagnosis. Adenoma / pathology. Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / pathology. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Myoepithelioma / diagnosis. Myoepithelioma / pathology. Staining and Labeling

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717754.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Buchner A, Merrell PW, Carpenter WM: Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. J Oral Pathol Med; 2007 Apr;36(4):207-14
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world.
  • BACKGROUND: The relative frequency of individual intra-oral minor salivary gland tumors (IMSGT) is not well documented in the literature.
  • Tumors were classified according to the 2005 WHO classification of salivary gland tumors.
  • Of the benign tumors, pleomorphic adenoma (PA) was the most common (39.2%), followed by cystadenoma (6.3%), canalicular adenoma (6.1%), ductal papillomas (4.4%), basal cell adenoma (1.6%), and myoepithelioma (1.3%).
  • Of the malignant tumors, mucoepidermoid carcinoma was the most common (21.8%), followed by polymorphous low-grade adenocarcinoma (7.1%), adenoid cystic carcinoma (6.3%), adenocarcinoma, not otherwise specified (NOS; 2.1%), acinic cell carcinoma (1.6%), clear cell carcinoma, NOS (1.0%), and carcinoma ex PA (0.5%).
  • To determine the true relative frequency, more studies should be conducted, on a large number of cases from one source, by experienced pathologists in the field of salivary gland tumors.
  • [MeSH-major] Salivary Gland Neoplasms / epidemiology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / epidemiology. Adenoma, Pleomorphic / pathology. Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / epidemiology. Carcinoma, Mucoepidermoid / pathology. Child. Cystadenoma / epidemiology. Cystadenoma / pathology. Female. Humans. Male. Middle Aged. Prevalence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391298.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


74. Bondioni S, Angioni AR, Corbetta S, Locatelli M, Ferrero S, Ferrante E, Mantovani G, Olgiati L, Beck-Peccoz P, Spada A, Lania AG: Effect of 9-cis retinoic acid on dopamine D2 receptor expression in pituitary adenoma cells. Exp Biol Med (Maywood); 2008 Apr;233(4):439-46
Hazardous Substances Data Bank. ALITRETINOIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 9-cis retinoic acid on dopamine D2 receptor expression in pituitary adenoma cells.
  • The aim of the study was to evaluate the effect of 9-cis retinoic acid (9-cis RA) on D2R protein expression in human pituitary adenomas and GH3 cell line.
  • Treatment with 9-cis RA (100 nM for 48 hrs) caused a 109 +/- 32% increase of basal D2R levels in five of eight growth hormone (GH)-secreting adenomas (GH-omas), a 129 +/- 28% increase in 7 of 11 nonfunctioning adenomas, and no effect in two resistant prolactinomas by Western blotting.
  • While the induction of D2R did not affect the slight but significant inhibitory effect exerted by dopamine (10 nM) on in vitro GH release by GH-oma cultured cells, in pituitary GH3 cell lines cis-9 RA enhanced the dopamine-induced inhibition of in vitro GH release (% inhibition: 16 +/- 2 versus 26 +/- 5, P < 0.05), cell proliferation (25 +/- 2% versus 44 +/- 5%, P < 0.05) and cell viability (16 +/- 0.8% versus 29 +/- 1%, P < 0.05), likely by activating caspase-3 (28 +/- 3% versus basal, P < 0.05).
  • In conclusion, this study provides novel evidence for a permissive role of retinoids on the expression of D2R in a good proportion of pituitary tumors and on the generation of pro-apoptotic signals in GH3 cell line.
  • [MeSH-minor] Animals. Apoptosis / physiology. Cell Line. Cell Proliferation. Cell Survival. Dopamine / metabolism. Humans. Protein Isoforms / genetics. Protein Isoforms / metabolism. Rats. Receptors, Retinoic Acid / genetics. Receptors, Retinoic Acid / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367633.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Receptors, Dopamine D2; 0 / Receptors, Retinoic Acid; 5300-03-8 / alitretinoin; 5688UTC01R / Tretinoin; VTD58H1Z2X / Dopamine
  •  go-up   go-down


75. Chao C, Han X, Ives K, Park J, Kolokoltsov AA, Davey RA, Moyer MP, Hellmich MR: CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells. Int J Cancer; 2010 Feb 15;126(4):864-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of gastrin and cholecystokinin 2 (CCK(2)) receptor splice variants (CCK(2)R and CCK(2i4sv)R) are upregulated in human colonic adenomas where they are thought to contribute to tumor growth and progression.
  • To determine the effects of ectopic CCK(2) receptor variant expression on colonic epithelial cell growth in vitro and in vivo, we employed the non-tumorigenic colonic epithelial cell line, NCM356.
  • NCM356 cells expressing either CCK(2)R or CCK(2i4sv)R (71 and 81 fmol/mg, respectively) grew faster in vitro, and exhibited an increase in basal levels of phosphorylated ERK (pERK), compared with vector.
  • Inhibitors of mitogen activated protein kinase pathway (MEK/ERK) or protein kinase C (PKC) isozymes partially inhibited the elevated levels of basal pERK and in vitro growth of receptor-expressing cells.
  • These findings support the hypothesis that expression of gastrin and its receptors in human colonic adenomas contributes to tumor growth and progression.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):745-81 [10581329.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):533-9 [10953028.001]
  • [Cites] J Biol Chem. 2000 Oct 13;275(41):32122-8 [10913157.001]
  • [Cites] Gut. 2000 Dec;47(6):820-4 [11076881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):751-6 [9012857.001]
  • [Cites] Am J Physiol. 1997 Oct;273(4 Pt 1):G891-8 [9357832.001]
  • [Cites] Gut. 1997 Sep;41(3):330-2 [9378387.001]
  • [Cites] Gastroenterology. 1998 Aug;115(2):275-80 [9679032.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):376-86 [10209952.001]
  • [Cites] Digestion. 1999;60(3):210-5 [10343134.001]
  • [Cites] Am J Physiol. 1999 Jun;276(6 Pt 1):G1363-72 [10362639.001]
  • [Cites] J Virol. 2005 Jan;79(2):756-63 [15613303.001]
  • [Cites] Cancer Lett. 2005 May 10;222(1):95-105 [15837546.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33368-73 [16079138.001]
  • [Cites] J Surg Res. 2005 Dec;129(2):313-21 [16051276.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1107-15 [16622436.001]
  • [Cites] Cardiovasc Hematol Disord Drug Targets. 2006 Jun;6(2):85-100 [16787194.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):1013-9 [16909104.001]
  • [Cites] Cancer Lett. 2007 Jul 8;252(1):19-35 [17188424.001]
  • [Cites] Curr Opin Pharmacol. 2007 Dec;7(6):583-92 [17997137.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jul;9(7):517-31 [18568040.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 6;1704(1):1-10 [15238241.001]
  • [Cites] Ann Intern Med. 1989 Nov 1;111(9):738-42 [2802432.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):22-30 [8514038.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4719-24 [11156225.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):625-31 [11212260.001]
  • [Cites] Annu Rev Physiol. 2001;63:119-39 [11181951.001]
  • [Cites] FEBS Lett. 2001 May 4;496(1):25-30 [11343700.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):567-73 [12189558.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48755-63 [12239223.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Jan;284(1):G75-84 [12488236.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:97-109 [15153424.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):190-5; discussion 195-6 [7840378.001]
  • (PMID = 19697327.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK058119-05; United States / NIDDK NIH HHS / DK / T32-DK007639; United States / NIDDK NIH HHS / DK / R01 DK058119; United States / NIDDK NIH HHS / DK / R01-DK058119; United States / NIDDK NIH HHS / DK / R01 DK058119-05; United States / NIDDK NIH HHS / DK / R01-DK048345
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Gastrins; 0 / Receptor, Cholecystokinin B; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS143954; NLM/ PMC2798930
  •  go-up   go-down


76. Hes O, Síma R, Nemcová J, Hora M, Bulimbasic S, Kazakov DV, Urge T, Reischig T, Dvorák M, Michal M: End-stage kidney disease: gains of chromosomes 7 and 17 and loss of Y chromosome in non-neoplastic tissue. Virchows Arch; 2008 Oct;453(4):313-9
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissues containing papillary adenomas (PA), clear (CRCC) and papillary renal cell carcinomas (PRCC), and myxoid liposarcoma (LPS) were examined using the same probes and compared with non-neoplastic tissue.
  • (2) Several tubules were hyperplastic, i.e., tubules with undifferentiated large epithelial cells, in which it was impossible to establish the specific type of a renal tubulus;.
  • The basal membranes were lined by large eosinophilic epithelial cells with polymorphic nuclei and pseudostratification.
  • Fluorescence in situ hybridization on tissues containing papillary adenomas, renal cell carcinomas, and liposarcoma revealed expected results, i.e., trisomy of chromosomes 7 and 17 in all PAs and PRCC.
  • We suggest that chromosomal changes typical of the papillary renal cell lesions, i.e., trisomies of chromosomes 7 and 17, are very frequent in non-neoplastic parenchyma of the end-stage kidney, and they have a tendency to a multifocal occurrence.
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Carcinoma, Renal Cell / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Kidney Tubules / pathology. Liposarcoma, Myxoid / genetics. Male. Middle Aged. Trisomy / genetics. Trisomy / pathology

  • Genetic Alliance. consumer health - Kidney Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):141-53 [16434887.001]
  • [Cites] J Pathol. 1997 Oct;183(2):131-3 [9390023.001]
  • [Cites] World J Urol. 2004 Jun;22(2):120-3 [14689223.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 1;89(1):65-8 [8689614.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):301-9 [10102616.001]
  • [Cites] J Pathol. 1998 Apr;184(4):424-9 [9664910.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9744-8 [1409692.001]
  • [Cites] Hum Genet. 1995 Feb;95(2):149-56 [7860060.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):1053-9 [14559990.001]
  • [Cites] J Urol. 2002 Dec;168(6):2632-6 [12441999.001]
  • [Cites] J Pathol. 1999 Feb;187(3):308-12 [10398084.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Jul;3(4):249-55 [1958590.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):443-51 [15767796.001]
  • [Cites] Cytogenet Cell Genet. 1995;69(1-2):90-6 [7835096.001]
  • [Cites] Transplantation. 1999 Aug 15;68(3):385-90 [10459542.001]
  • [Cites] J Urol. 2006 Jun;175(6):2018-20; discussion 2021 [16697788.001]
  • [Cites] J Am Soc Nephrol. 1996 Nov;7(11):2461-8 [8959640.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1117-24 [7943532.001]
  • [Cites] J Urol. 2005 Aug;174(2):731-5 [16006966.001]
  • [Cites] Urology. 1999 Apr;53(4):684-9 [10197841.001]
  • (PMID = 18795325.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


77. Gassler N, Herr I, Schneider A, Penzel R, Langbein L, Schirmacher P, Kopitz J: Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas. J Pathol; 2005 Nov;207(3):295-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, gene expression, protein synthesis, and enzymatic activity of ACS5 in sporadic colorectal adenocarcinomas, adenomas, and established cell lines were analysed using RT-PCR, western blot analysis, immunofluorescence, and an enzymatic assay.
  • Enhanced expression of ACS5 mRNA and protein as well as enzymatic activity was found in adenomas and in 11 (73%; group 1) of 15 colorectal adenocarcinomas investigated, while a decrease of ACS5 was seen in four tumours (27%; group 2).
  • However, basal ACS5 enzymatic activity was increased as a percentage of the total activity of ACSs in both groups, arguing for an absolute (group 1) or relative (group 2) increase in ACS5 enzymatic activity in all adenocarcinomas investigated.
  • These findings are reflected by in vitro analysis of three established colorectal adenocarcinoma cell lines, in which activity of ACS5 occurred.
  • [MeSH-minor] Adenoma / enzymology. Adenoma / genetics. Adenoma / metabolism. Aged. Aged, 80 and over. Cell Line, Tumor. Colon / enzymology. Colon / metabolism. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Intestinal Mucosa / metabolism. Male. Middle Aged. Neoplasm Proteins / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Rectum / enzymology. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16110457.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.- / acyl CoA synthetase 5
  •  go-up   go-down


78. Lim JS, Ku CR, Lee MK, Kim TS, Kim SH, Lee EJ: A case of fugitive acromegaly, initially presented as invasive prolactinoma. Endocrine; 2010 Aug;38(1):1-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fugitive acromegaly is most commonly caused by pituitary acidophil stem cell adenomas, and is characterized by a relatively short clinical history, a large and locally invasive tumor, and relatively low hormonal activity.
  • He had undergone transsphenoidal surgery in November 1999 because of a large invasive prolactinoma.
  • An oral glucose tolerance test revealed that basal and nadir levels of growth hormone (GH) were 1.56 and 1 ng/ml, respectively.
  • Double immunofluorescence staining showed a mixed positivity for GH and PRL in the majority of tumor cells; however, the two hormones colocalized in a minority of tumor cells, indicating that the tumor was composed of three different cell types (GH, PRL, and GH/PRL).
  • The diagnosis of fugitive acromegaly was initially overlooked in this patient because of normal serum GH levels and a lack of acromegalic features, although histological evidence for GH production was present.
  • IGF-1 determinations would be helpful for the diagnosis of fugitive acromegaly.

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1998 Oct;83(10):3419-26 [9768641.001]
  • [Cites] Croat Med J. 2007 Feb;48(1):87-91 [17309144.001]
  • [Cites] Tumour Biol. 1993;14(1):59-68 [8493452.001]
  • [Cites] Int J Cancer. 2010 Apr 15;126(8):1806-16 [19739079.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1381-8 [12727930.001]
  • [Cites] Eur J Endocrinol. 2007 Feb;156(2):203-16 [17287410.001]
  • [Cites] Endocr J. 2008 May;55(2):351-7 [18379126.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3409-16 [10999842.001]
  • [Cites] Pituitary. 2003;6(1):19-27 [14674720.001]
  • [Cites] Pituitary. 2009;12 (3):261-4 [19003539.001]
  • [Cites] Endocr J. 2002 Feb;49(1):41-7 [12008749.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6377-86 [18676863.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):761-71 [6261917.001]
  • [Cites] Eur J Endocrinol. 2006 Mar;154(3):467-77 [16498061.001]
  • [Cites] Clin Endocrinol (Oxf). 2009 Jul;71(1):86-91 [19018786.001]
  • [Cites] Hormones (Athens). 2005 Jul-Sep;4(3):165-70 [16613827.001]
  • [Cites] Can J Neurol Sci. 1997 Aug;24(3):250-3 [9276113.001]
  • [Cites] Pituitary. 1999;1(2):91-8 [11081186.001]
  • [Cites] Orphanet J Rare Dis. 2008 Jun 25;3:17 [18578866.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):68-75 [1352308.001]
  • [Cites] N Engl J Med. 1979 Nov 22;301(21):1138-42 [492275.001]
  • (PMID = 20960094.001).
  • [ISSN] 1559-0100
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9002-62-4 / Prolactin
  •  go-up   go-down


79. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol; 2006 Jan;42(1):57-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours.
  • In the present study we analysed the expression of this molecule in salivary gland tumours.
  • Archival formalin-fixed, paraffin-embedded sections of 40 benign and 57 malignant salivary gland tumours were retrieved and retrospectively studied immunohistochemically using a polyclonal C-KIT antibody in an Envision/HRP technique.
  • In addition five samples of chronic submandibular sialadenitis, five normal minor salivary glands and parotid or submandibular gland tissue adjacent to benign tumour were also studied.
  • C-KIT expression was observed in cases of adenoid cystic, acinic cell polymorphous low grade, epithelial-myoepithelial, carcinosarcoma and basal cell adenocarcinomas, as in luminal cells of pleomorphic adenomas, in serous acinar and only in intercalated and a small number of striated ductal cells of inflammatory salivary gland tissue, whereas normal salivary lobules were generally negative except a weak positivity of intercalated cells.
  • Contrary to other reports, this study suggests that, C-KIT protein does not appear to be an exclusively specific marker for benign or malignant salivary gland neoplasms, but may be useful in differential diagnosis of adenoid cystic carcinoma from polymorphous low grade adenocarcinoma.
  • Furthermore its expression in serous acinar cells in sialadenitis and intercalated ductal cells in normal and inflammatory lesions may indicate a possible participation in pathogenesis of both neoplastic and non-neoplastic salivary gland diseases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis. Salivary Gland Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


80. National Toxicology Program: Toxicology and carcinogenesis studies of propargyl alcohol (CAS No. 107-19-7) in F344/N rats and B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser; 2008 Sep;(552):1-172
Hazardous Substances Data Bank. PROPARGYL ALCOHOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nasal respiratory epithelial adenomas were present in three 64 ppm males and one 32 ppm female; the incidence in 64 ppm males exceeded the historical control ranges.
  • The incidences of respiratory epithelial hyperplasia, respiratory glandular hyperplasia, and olfactory basal cell hyperplasia were significantly increased in all exposed groups of rats.
  • The incidence of mononuclear cell leukemia was significantly increased in males exposed to 64 ppm, and the incidence exceeded the historical control ranges.
  • Eye abnormality (unspecified) was observed after one full year of exposure with the incidence increasing in an exposure concentration-related manner.
  • The incidences of nasal respiratory epithelial adenoma increased with a positive trend and were significantly increased in groups exposed to 32 ppm.
  • Significantly increased incidences of Harderian gland adenoma occurred in 8 and 32 ppm males.
  • CONCLUSIONS: Under the conditions of these 2-year inhalation studies, there was some evidence of carcinogenetic activity of propargyl alcohol in male F344/N rats based on increased incidences of nasal respiratory epithelial adenoma and mononuclear cell leukemia.
  • There was some evidence of carcinogenic activity of propargyl alcohol in male and female B6C3F1 mice based on increased incidences of nasal respiratory epithelial adenoma.
  • The increased incidences of Harderian gland adenoma in male B6C3F1 mice may have been related to exposure to propargyl alcohol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18974778.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkynes; 0 / Propanols; E920VF499L / propargyl alcohol
  •  go-up   go-down


81. Ueo T, Kashima K, Daa T, Kondo Y, Sasaki A, Yokoyama S: Immunohistochemical analysis of morules in colonic neoplasms: morules are morphologically and qualitatively different from squamous metaplasia. Pathobiology; 2005;72(5):269-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten cases of morule-associated colonic neoplasms (4 adenocarcinomas, 1 adenoma with carcinoma in situ, and 5 adenomas), and 3 cases of squamous metaplasia in colonic adenocarcinoma were examined morphologically and immunohistochemically.
  • Furthermore, p63 and 34betaE12 positivities in morules suggested that they have a basal/stem cell phenotype.
  • We consider that morules in colonic neoplasms are cell clusters with a basal/stem cell phenotype, and have less proliferative and less invasive potential than other cancer cells.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Carcinoma in Situ / pathology. Colonic Neoplasms / pathology. Immunoenzyme Techniques / methods. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Female. Humans. Intranuclear Inclusion Bodies / chemistry. Intranuclear Inclusion Bodies / ultrastructure. Male. Metaplasia / metabolism. Metaplasia / pathology. Middle Aged. beta Catenin / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374071.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  •  go-up   go-down


82. Ilie M, Hofman V, Pedeutour F, Attias R, Santini J, Hofman P: Oncocytic lipoadenoma of the parotid gland: Immunohistochemical and cytogenetic analysis. Pathol Res Pract; 2010 Jan 15;206(1):66-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic lipoadenoma of the parotid gland: Immunohistochemical and cytogenetic analysis.
  • Salivary gland oncocytic lipoadenoma is an exceptional benign tumor composed of mature adipose tissue associated with a mixture of oncocytes.
  • A 64-year-old male developed a left parotid gland, well-encapsulated tumor measuring 3.5 x 3 cm(2), showing mature fat cells associated with oncocytic changes of epithelial components.
  • Immunohistochemistry showed a dual epithelial population with ductal (positivity for AE1/AE3, CK19, CK7 antibodies) and basal-cell (positivity for p63, CK14, CK5,6 antibodies) differentiation in oncocytic areas.
  • Such alterations in HMGA2 have been described in both lipomas and pleomorphic adenomas of the salivary glands.
  • [MeSH-major] Adenoma / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19346081.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


83. National Toxicology Program: Toxicology and carcinogenesis studies of alpha-methylstyrene (Cas No. 98-83-9) in F344/N rats and B6C3F1 mice (inhalation studies). Natl Toxicol Program Tech Rep Ser; 2007 Nov;(543):1-210
Hazardous Substances Data Bank. ALPHA-METHYL STYRENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morphologic changes were not detected in the liver.
  • Two 1,000 ppm males and one 300 ppm male had renal tubule carcinomas, and one 300 ppm male had a renal tubule adenoma.
  • Because of the neoplasms observed in 300 and 1,000 ppm males at the end of the 2-year study and the finding of alpha2μ-globulin accumulation in the kidneys at 3 months, which is often associated with kidney neoplasms, additional step sections of kidney were prepared; additional males with focal hyperplasia or adenoma were identified.
  • The incidences of renal tubule adenoma and carcinoma (combined) in the 1,000 ppm males were significantly greater than those in the chamber controls when the single and step sections were combined.
  • The incidence of mononuclear cell leukemia in 1,000 ppm males was significantly increased compared to the chamber controls.
  • In the nose, the incidences of basal cell hyperplasia were significantly increased in all exposed groups of males and females, and the incidences of degeneration of the olfactory epithelium were increased in 1,000 ppm males and females and 300 ppm females.
  • The incidences of hepatocellular adenoma or carcinoma (combined) were significantly increased in the 100 and 600 ppm males and in all exposed groups of females.
  • The incidences of hepatocellular adenoma were significantly increased in all exposed groups of females, and the incidences in all exposed groups of males and females exceeded the historical range for chamber controls.
  • CONCLUSIONS: Under the conditions of this 2-year inhalation study, there was some evidence of carcinogenic activity of alpha-methylstyrene in male F344/N rats based on increased incidences of renal tubule adenomas and carcinomas (combined).
  • The increased incidence of mononuclear cell leukemia in 1,000 ppm male F344/N rats may have been related to alpha-methylstyrene exposure.
  • There was equivocal evidence of carcinogenic activity of alpha-methylstyrene in male B6C3F1 mice based on marginally increased incidences of hepatocellular adenoma or carcinoma (combined).
  • There was clear evidence of carcinogenic activity of alpha-methylstyrene in female B6C3F1 mice based on increased incidences of hepatocellular adenomas and carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18685715.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Carcinogens; 0 / Mutagens; 0 / Styrenes; 98-83-9 / alpha-methylstyrol
  •  go-up   go-down


84. Wang Y, Zhou ZG, Xia QJ, Zhang WY, Li HG, Wang R: [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):465-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance].
  • OBJECTIVE: To investigate the expression differences of minichromosome maintenance 2 (MCM2) mRNA and protein among colon adenocarcinoma, colon adenoma and normal mucosa, and among different clinicopathological types of adenomas.
  • METHODS: Fifty specimens, including 33 colonic adenomas, 12 colonic adenocarcinomas and 5 normal colonic mucosa were selected.
  • Expression differences of MCM2 mRNA among the colonic adenocarcinoma, adenoma and normal colonic mucosa were evaluated by REST-XL software.
  • RESULTS: The expression of MCM2 was observed in the basal third to half of the colonic crypts in normal mucosa, while throughout the epithelium in the colonic adenocarcinomas and adenomas.
  • However, the expression of MCM2 mRNA in the adenocarcinomas was significantly higher than that in the adenomas(P=0.001).
  • The MCM2 mRNA expression was elevated in the adenoma with villous type, in the conditions of high-grade dysplasia, larger size, sessile morphology and in patients of older ages, but the difference was not significant by REST-XL (P>0.05).
  • CONCLUSION: The difference of MCM2 expression between the adenoma and the adenocarcinoma indicates its potential value in the early diagnosis of colonic cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Cycle Proteins / metabolism. Colonic Neoplasms / metabolism. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803052.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


85. Went PT, Sauter G, Oberholzer M, Bubendorf L: Abundant expression of AMACR in many distinct tumour types. Pathology; 2006 Oct;38(5):426-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Alpha-methylacyl-CoA racemase (AMACR), a mitochondrial and peroxisomal enzyme, is a valuable tool to confirm the diagnosis of prostate cancer, especially if combined with basal cell markers.
  • RESULTS: Microarray analysis revealed that tumours with prominent AMACR expression included adenocarcinomas of the prostate (72%), hepatocellular carcinomas (77%), papillary renal cell carcinomas (70%), and colorectal adenocarcinomas (71%).
  • AMACR expression was equally frequent in colorectal adenomas and carcinomas.
  • In the thyroid, AMACR expression was found in 42% of the follicular carcinomas but in only 16% of follicular adenomas.
  • However, a more detailed analysis on a thyroid tissue microarray did not confirm a significant difference of AMACR expression in follicular adenoma and carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008281.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


86. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • These results suggested the potential value of MCM2 in early diagnosis of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


87. Anand BS, Verstovsek G, Cole G: Tubulovillous adenoma of anal canal: a case report. World J Gastroenterol; 2006 Mar 21;12(11):1780-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of anal canal: a case report.
  • Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma.
  • We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis.
  • Microscopic examination revealed a tubulovillus adenoma with no areas of high grade dysplasia or malignant transformation.
  • We believe the tubulovillus adenoma arose from either an anal gland or its duct that opens into the anus.
  • [MeSH-major] Adenoma, Villous / diagnosis. Anus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal / pathology. Cell Transformation, Neoplastic. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • (PMID = 16586552.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4124358
  •  go-up   go-down


88. Tsybrovskyy O, Rössmann-Tsybrovskyy M: Oncocytic versus mitochondrion-rich follicular thyroid tumours: should we make a difference? Histopathology; 2009 Dec;55(6):665-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To separate true oncocytic neoplasms from mitochondrion-rich non-oncocytic lesions based on the intracellular relationship between major cell organelles, and to establish the diagnostic and clinical relevance of this distinction.
  • METHODS AND RESULTS: Tissue samples from 276 follicular adenomas, 194 follicular carcinomas, 162 normal thyroids and 296 non-neoplastic lesions were classified as conventional, mitochondrion-rich or oncocytic based on the immunohistochemically assessed quantity and intracellular distribution of mitochondria and endoplasmic reticulum (ER) and nuclear position.
  • In oncocytes, densely packed mitochondria resulted in homogeneous immunolabelling of basal cytoplasmic regions, whereas ER and the nuclei were typically displaced to the apical position.
  • CONCLUSIONS: True oncocytic neoplasms can be distinguished from mitochondrion-rich non-oncocytic tumours based on aberrant distribution of all major cell organelles.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Mitochondria / pathology. Oxyphil Cells / pathology. Thyroid Neoplasms / classification. Thyroid Neoplasms / pathology
  • [MeSH-minor] Cell Count. Disease-Free Survival. Humans. Immunohistochemistry. Microscopy, Electron. Regression Analysis. Statistics, Nonparametric. Survival Analysis. Thyroid Gland / metabolism. Thyroid Gland / pathology. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002768.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Fan XS, Wu HY, Yu HP, Zhou Q, Zhang YF, Huang Q: Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with beta-catenin. Int J Colorectal Dis; 2010 May;25(5):583-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUNDS AND AIMS: Lgr5 is a member of the G protein receptor super-family and was shown recently to be a stem cell marker for cells with intestinal differentiation.
  • Its over-expression has been demonstrated in hepatocellular, basal cell carcinoma, and ovarian cancers but the underlying mechanisms are poorly understood.
  • METHODS: The study was carried out on a tissue microarray that consisted of 102 colorectal carcinomas (CRC; M:F = 55:47), 18 colon adenoma, and 12 colon normal mucosa cases.
  • RESULTS: Lgr5 immunoreactivity was observed only in single cells in the base of normal colon mucosal crypts but high in 28% (five out of 18) adenomas, and significantly higher in 54% (55/102, p = 0.016) CRC cases.
  • In normal mucosa, adenoma, and CRC, beta-catenin expression was seen in 25% (three out of 12), 27% (five out of 18), and 81% (83/102) cases, respectively, in contrast to 0, 0, and 40% (41/102) for p53 expression, respectively.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Anat. 2008 Jul;213(1):52-8 [18638070.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):379-83 [9697701.001]
  • [Cites] Front Biosci. 2008 May 01;13:3352-63 [18508437.001]
  • [Cites] Mol Endocrinol. 1998 Dec;12(12):1830-45 [9849958.001]
  • [Cites] Hepatology. 2003 Mar;37(3):528-33 [12601349.001]
  • [Cites] Mol Endocrinol. 2000 Feb;14(2):272-84 [10674399.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17 ):6027-32 [15837931.001]
  • [Cites] Science. 2004 Mar 12;303(5664):1684-6 [15017003.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2862-70 [18539965.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Int J Surg Pathol. 2007 Jan;15(1):38-52 [17172496.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):363-71 [16489634.001]
  • [Cites] Transl Res. 2008 Jan;151(1):10-6 [18061123.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):835-43 [18688030.001]
  • [Cites] Cell Signal. 2007 Dec;19(12):2428-33 [17651940.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] ScientificWorldJournal. 2008 Nov 23;8:1168-76 [19030762.001]
  • [Cites] Nat Genet. 2004 Oct;36(10 ):1117-21 [15378062.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2828-38 [18539961.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):387-98 [18432252.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:675-99 [17645413.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4042-5 [17634527.001]
  • [Cites] Annu Rev Physiol. 2009;71:241-60 [18808327.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:351-6 [19478326.001]
  • [Cites] Adv Pathobiol. 1977;(6):141-52 [899956.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(22):9736-43 [15509778.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):419-26 [16575208.001]
  • [Cites] Pathobiology. 2006;73(5):213-23 [17314492.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):755-68 [18784658.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1904-9 [15790842.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3304-13 [18451157.001]
  • (PMID = 20195621.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / LGR5 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin
  •  go-up   go-down


90. Kim IM, Ackerson T, Ramakrishna S, Tretiakova M, Wang IC, Kalin TV, Major ML, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV: The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res; 2006 Feb 15;66(4):2153-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proliferation-specific Forkhead Box m1 (Foxm1 or Foxm1b) transcription factor (previously called HFH-11B, Trident, Win, or MPP2) regulates expression of cell cycle genes essential for progression into DNA replication and mitosis.
  • Expression of Foxm1 is found in a variety of distinct human cancers including hepatocellular carcinomas, intrahepatic cholangiocarcinomas, basal cell carcinomas, ductal breast carcinomas, and anaplastic astrocytomas and glioblastomas.
  • In this study, we show that human Foxm1 protein is abundantly expressed in highly proliferative human non-small cell lung cancers (NSCLC) as well as in mouse lung tumors induced by urethane.
  • We show that Mx-Cre Foxm1-/- mice exhibit diminished proliferation of lung tumor cells causing a significant reduction in number and size of lung adenomas.
  • Transient transfection experiments with A549 lung adenocarcinoma cells show that depletion of Foxm1 levels by short interfering RNA caused diminished DNA replication and mitosis and reduced anchorage-independent growth of cell colonies on soft agar.
  • Foxm1-depleted A549 cells exhibit reduced expression of cell cycle-promoting cyclin A2 and cyclin B1 genes.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Forkhead Transcription Factors / physiology. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Alleles. Animals. Cell Adhesion. Cell Growth Processes / physiology. Cyclin A / biosynthesis. Cyclin A / genetics. Cyclin A2. Cyclin B / biosynthesis. Cyclin B / genetics. Cyclin B1. DNA Replication. DNA, Neoplasm / biosynthesis. Gene Deletion. Humans. Mice. Mice, Inbred C57BL. Mice, Transgenic. Mitosis. RNA, Small Interfering / genetics. Urethane

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16489016.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 54687-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCNA2 protein, human; 0 / CCNB1 protein, human; 0 / Ccnb1 protein, mouse; 0 / Cyclin A; 0 / Cyclin A2; 0 / Cyclin B; 0 / Cyclin B1; 0 / DNA, Neoplasm; 0 / FOXM1 protein, human; 0 / Forkhead Transcription Factors; 0 / Foxm1 protein, mouse; 0 / RNA, Small Interfering; 3IN71E75Z5 / Urethane
  •  go-up   go-down


91. Katona TM, Billings SD, Montironi R, Lopez-Beltran A, Cheng L: Expression of OCT4 transcription factor in cutaneous neoplasia. Appl Immunohistochem Mol Morphol; 2007 Dec;15(4):359-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, immunohistochemical expression of OCT4 protein has been described in the cells within the basal layer of normal human and canine epidermis.
  • We have examined a series of basal cell carcinomas and adnexal tumors of related histogenesis, in an effort to corroborate the above findings and to assess for expression of OCT4 protein in neoplasia of the infundibulo-apocrine-sebaceous unit.
  • We analyzed OCT4 expression in 115 cutaneous specimens including 26 basal cell carcinomas, 12 benign follicular tumors (10 trichoepitheliomas and 2 trichoblastomas), 10 benign apocrine tumors, 12 sebaceous hyperplasia lesions, 10 sebaceous adenomas, 4 sebaceous carcinomas, 13 nevi sebacei of Jadassohn, 8 squamous cell carcinomas (including one spindle-cell squamous cell carcinoma), 8 compound melanocytic nevi, 5 Merkel cell carcinomas, 3 pilar cysts, 1 scar, 2 nonspecific, mild superficial perivascular dermatitis specimens, and 1 non-scarring alopecia.
  • In contrast to previous studies, our data indicate that the OCT4 expression is not retained in cutaneous neoplasms derived from basal epidermis or related adnexal neoplasms, including lesions of the scalp.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091376.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


92. Roelfsema F, Kok S, Kok P, Pereira AM, Biermasz NR, Smit JW, Frolich M, Keenan DM, Veldhuis JD, Romijn JA: Pituitary-hormone secretion by thyrotropinomas. Pituitary; 2009;12(3):200-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormone secretion by somatotropinomas, corticotropinomas and prolactinomas exhibits increased pulse frequency, basal and pulsatile secretion, accompanied by greater disorderliness.
  • TSH burst frequency and basal and pulsatile secretion were increased in patients compared with controls.
  • We conclude that TSH secretion by thyrotropinomas shares many characteristics of other pituitary hormone-secreting adenomas.
  • [MeSH-major] Adenoma / physiopathology. Pituitary Hormones / blood. Pituitary Hormones / secretion. Pituitary Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 1994 Oct;131(4):331-40 [7921220.001]
  • [Cites] J Clin Invest. 1994 Sep;94(3):1277-88 [8083369.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Dec;79(6):1706-15 [7989479.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2518-22 [7543115.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14100-5 [8943067.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Nov;47(5):599-612 [9425400.001]
  • [Cites] Thyroid. 1998 Jan;8(1):9-14 [9492147.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):476-86 [10022404.001]
  • [Cites] Eur J Endocrinol. 1999 Mar;140(3):192-200 [10216513.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 Feb;288(2):R440-6 [15486096.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):176-81 [15670193.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1570-7 [15598691.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E160-5 [15727954.001]
  • [Cites] Tissue Cell. 2005 Aug;37(4):269-80 [15921714.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6185-91 [16091498.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16880-5 [16272219.001]
  • [Cites] Eur J Endocrinol. 2007 Jul;157(1):39-46 [17609400.001]
  • [Cites] J Neuroendocrinol. 2008 Jan;20(1):1-70 [18081553.001]
  • [Cites] J Neurosurg. 2008 Jul;109(1):17-22 [18590428.001]
  • [Cites] J Neuroendocrinol. 2008 Jun;20(6):687-91 [18601690.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Sep;285(3):R664-73 [12738612.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2290-300 [15126555.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 1):E948-57 [10567024.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1487-91 [10770186.001]
  • [Cites] Methods Enzymol. 2000;321:149-82 [10909056.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):700-12 [11158034.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Mar;280(3):R721-9 [11171650.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Jun;280(6):R1755-71 [11353681.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3304-10 [11443205.001]
  • [Cites] Mol Endocrinol. 2001 Sep;15(9):1529-38 [11518802.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5572-6 [11701737.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Jan;1(1-2):97-108 [11704998.001]
  • [Cites] J Neurooncol. 2001 Sep;54(2):179-86 [11761434.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):219-28 [12227947.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):433-42 [12656664.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Jun;60(6):765-72 [15163342.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):147-53 [15185102.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Aug;65(2):315-20 [3597710.001]
  • [Cites] Acta Neuropathol. 1988;76(5):458-64 [2847475.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jun;68(6):1211-5 [2723029.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Jun;70(6):1631-6 [2347898.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Dec;71(6):1616-23 [2172282.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Feb;72(2):415-21 [1704010.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Feb;72(2):477-83 [1704011.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Dec;73(6):1281-8 [1955510.001]
  • [Cites] Clin Endocrinol (Oxf). 1992 Dec;37(6):504-10 [1286520.001]
  • [Cites] Ann Intern Med. 1993 Aug 1;119(3):236-40 [8323093.001]
  • [Cites] Eur J Endocrinol. 1994 Feb;130(2):113-20 [8130883.001]
  • [Cites] Eur J Endocrinol. 1994 Oct;131(4):355-8 [7921223.001]
  • (PMID = 19051037.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000585
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pituitary Hormones; 67763-96-6 / Insulin-Like Growth Factor I; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone
  • [Other-IDs] NLM/ PMC2712623
  •  go-up   go-down


93. Tamura T, Mitsumori K, Totsuka Y, Wakabayashi K, Kido R, Kasai H, Nasu M, Hirose M: Absence of in vivo genotoxic potential and tumor initiation activity of kojic acid in the rat thyroid. Toxicology; 2006 May 15;222(3):213-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rats given four times by s.c. injection of N-bis(2-hydroxypropyl)nitrosamine (DHPN; 700 mg/kg bw) during the initiation period followed by administration of 0.1% SDM and rats given diet containing 2% KA for the initial 8 weeks or for the entire 31 weeks of the experiment, or basal diet alone were provided as controls.
  • In the two-stage thyroid tumorigenesis model, neither adenomas nor carcinomas were induced in the groups given 0, 0.02, 0.2 or 2% KA followed by 0.1% SDM administration, and incidences and multiplicities of focal follicular cell hyperplasias did not demonstrate any significant intergroup differences at the end of administration and recovery periods.
  • In contrast, incidences and multiplicities of focal follicular cell hyperplasias, adenomas and carcinomas were all significantly increased in the DHPN + 0.1% SDM group.
  • Although the incidences and multiplicities of focal follicular cell hyperplasias in the group given 2% KA for 31 weeks were greater than those in the 2% KA + 0.1% SDM group and an adenoma was observed in a rat at the end of the recovery period, no development of carcinomas was evident at either time point.
  • [MeSH-major] Carcinogens / toxicity. Pyrones / toxicity. Thyroid Gland / drug effects. Thyroid Neoplasms / chemically induced
  • [MeSH-minor] Adenoma / chemically induced. Adenoma / pathology. Animals. Carcinoma / chemically induced. Carcinoma / pathology. DNA Adducts / metabolism. Deoxyguanosine / analogs & derivatives. Deoxyguanosine / metabolism. Hyperplasia / chemically induced. Hyperplasia / pathology. Male. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. KOJIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16603304.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Carcinogens; 0 / DNA Adducts; 0 / Pyrones; 6K23F1TT52 / kojic acid; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


94. Chlumská A, Benes Z, Mukensnabl P, Zámecník M: Histologic findings after sodium phosphate bowel preparation for colonoscopy. Diagnostic pitfalls of colonoscopic biopsies. Cesk Patol; 2010 Apr;46(2):37-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to edema and hemorrhage, in 26 patients (61.9%), patchy mononuclear infiltration in the upper part of lamina propria and increased epithelial cell proliferation of individual crypts were seen.
  • In 5 patients (11.9%), some biopsy samples contained scattered neutrophilic leucocytes in the lamina propria/superficial epithelium, isolated basal cryptitis, increased proliferation and apoptosis of the crypt epithelium.
  • Mild basal cryptitis, increased proliferation and striking apoptosis were present in two inflammatory pseudopolyps (in two patients).
  • In 4 patients, solitary tubular adenomas with low-grade dysplasia without any reactive changes were found.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21275224.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Cathartics; 0 / Phosphates; SE337SVY37 / sodium phosphate
  •  go-up   go-down


95. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ: Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab; 2005 Aug;289(2):E278-87
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a series of human corticotroph adenomas, we recently found predominant mRNA expression of somatostatin (SS) receptor subtype 5 (sst5).
  • After 72 h, the multiligand SS analog SOM230, which has a very high sst5 binding affinity, but not Octreotide (OCT), significantly inhibited basal ACTH release.
  • SOM230 showed a 7-fold higher ligand binding affinity and a 19-fold higher potency in stimulating guanosine 5'-O-(3-thiotriphosphate) binding in AtT-20 cell membranes compared with OCT.
  • [MeSH-major] Adrenocorticotropic Hormone / secretion. Corticotropin-Releasing Hormone / physiology. Pituitary Gland / secretion. Receptors, Somatostatin / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15769796.001).
  • [ISSN] 0193-1849
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIM 23268; 0 / Glucocorticoids; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 51110-01-1 / Somatostatin; 9002-60-2 / Adrenocorticotropic Hormone; 9015-71-8 / Corticotropin-Releasing Hormone; 98H1T17066 / pasireotide; RWM8CCW8GP / Octreotide
  •  go-up   go-down


96. Deng J, Fujimoto J, Ye XF, Men TY, Van Pelt CS, Chen YL, Lin XF, Kadara H, Tao Q, Lotan D, Lotan R: Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila); 2010 Apr;3(4):424-37
Guide to Pharmacology. gene/protein/disease-specific - Class C Orphans - overview and references .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Examination of normal lung tissue and tumors from 51 Gprc5a(+/+) (adenoma incidence, 9.8%; adenocarcinoma, 0%) and 38 Gprc5a(-/-) mice (adenoma, 63%; adenocarcinoma, 21%) revealed macrophage infiltration into lungs of 45% of the Gprc5a(-/-) mice and 8% of Gprc5a(+/+) mice and the direct association of macrophages with 42% of adenomas and 88% of adenocarcinomas in the knockout mice.
  • Studies with epithelial cells cultured from tracheas of Gprc5a(-/-) and Gprc5a(+/+) mice revealed that Gprc5a loss is associated with increased cell proliferation, resistance to cell death in suspension, and increased basal, tumor necrosis factor alpha-induced, and lipopolysaccharide-induced NF-kappaB activation, which were reversed partially in Gprc5a(-/-) adenocarcinoma cells by reexpression of Gprc5a.
  • Thus, Gprc5a loss enhances NF-kappaB activation in lung epithelial cells, leading to increased autocrine and paracrine interactions, cell autonomy, and enhanced inflammation, which may synergize in the creation of a tumor-promoting microenvironment.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [CommentIn] Cancer Prev Res (Phila). 2010 Apr;3(4):403-5 [20354166.001]
  • (PMID = 20354164.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, G-Protein-Coupled
  •  go-up   go-down


97. Nolan LA, Schmid HA, Levy A: Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary. Endocrinology; 2007 Jun;148(6):2821-7
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acting principally through the latter, it inhibits basal and CRH-stimulated ACTH secretion from the AtT20 corticotroph cell line and ACTH release from a proportion of human corticotroph adenomas both in vitro and in vivo.
  • Pasireotide and octreotide had no effect on baseline pituitary cell turnover and no measurable effects on apoptosis.
  • Nevertheless, pasireotide and octreotide did not diminish the increase in ACTH-immunopositive cell index after adrenalectomy, indicating that cell division and differentiation of hormonally null cells in the pituitary are under independent control.
  • In conclusion, basal cell turnover in the pituitary is not inhibited by pasireotide or octreotide.
  • Cell division after bilateral adrenalectomy occurs in a specific subpopulation of hormonally null cells that are equally sensitive to the antiproliferative effects of pasireotide and octreotide, implicating SSTR2 receptors in this antimitotic response.
  • [MeSH-major] Adrenalectomy. Mitosis / drug effects. Octreotide / pharmacology. Pituitary Gland, Anterior / drug effects. Receptors, Somatostatin / agonists. Somatostatin / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347306.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 0 / Sstr2 protein, rat; 51110-01-1 / Somatostatin; 9002-60-2 / Adrenocorticotropic Hormone; 98H1T17066 / pasireotide; RWM8CCW8GP / Octreotide
  •  go-up   go-down


98. Rubinfeld H, Hadani M, Barkai G, Taylor JE, Culler MD, Shimon I: Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas. J Clin Endocrinol Metab; 2006 Jun;91(6):2257-63
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
  • SETTING: This study was performed in the endocrine laboratory of a tertiary academic medical center.
  • MATERIALS: Primary cell cultures of human fetal (21-25 wk gestation) pituitary tissues and cultured hormone-secreting adenoma cells were used in this study.
  • INTERVENTIONS: Cell cultures were incubated with CST-14 or CST-17, somatostatin, GHRH, SSTR analogs, and ghrelin analogs, and hormone secretion was analyzed.
  • CST-14 or CST-17 (10 nm) inhibited basal GH secretion in six of the 13 GH-cell adenomas and two of the three GH-PRL mixed adenomas.
  • CST-17 (100 nm) suppressed the GH response to GHRH and ghrelin analog (10 nm each) by 30-50% in adenomas (P < 0.05).
  • Three PRL-adenomas treated with CST-17 (10 nm) showed a 20-40% inhibition of PRL release (P < 0.05), whereas in three others no suppression or mild response was achieved at this concentration.
  • RT-PCR revealed the expression of both SSTR2 and SSTR5 in all GH-cell and mixed adenomas studied and all PRL-secreting adenomas studied, except for two of the CST-resistant prolactinomas, in which SSTR5 was absent.
  • The regulation of PRL release from cultured adenomas appears to be primarily mediated by SSTR5.
  • [MeSH-major] Adenoma / secretion. Fetus / secretion. Human Growth Hormone / secretion. Neuropeptides / pharmacology. Pituitary Gland / drug effects. Pituitary Neoplasms / secretion. Prolactin / secretion. Prolactinoma / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595604.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuropeptides; 0 / cortistatin; 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


99. Birkenkamp-Demtröder K, Wagner L, Brandt Sørensen F, Bording Astrup L, Gartner W, Scherübl H, Heine B, Christiansen P, Ørntoft TF: Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology; 2005;82(2):121-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous microarray-based studies identified secretagogin to be highly expressed in normal colon mucosa compared to basal expression in colon adenocarcinomas.
  • Tissues adjacent to benign hyperplasic polyps and adenomas showed a decreased number of secretagogin-expressing neuroendocrine cells.
  • Secretagogin was strongly expressed in the cytosol and the nucleus of 19 well-differentiated neuroendocrine carcinoids and carcinoid metastases, as well as in neuroendocrine tumors from the lung, pancreas and adrenal gland.
  • Combined immunohistochemical analysis of secretagogin and FK506-binding protein 65, a protein de novo synthesized in adenocarcinomas, distinguished well-differentiated carcinoids, adenocarcinoids and undifferentiated carcinomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Blotting, Western. Carcinoid Tumor / metabolism. Carcinoid Tumor / pathology. Cell Differentiation / physiology. Chromogranin A. Chromogranins / metabolism. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Microscopy, Fluorescence. Middle Aged. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Peptidylprolyl Isomerase / metabolism. Phosphopyruvate Hydratase / metabolism. Secretagogins. Synaptophysin / metabolism. Tacrolimus Binding Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449819.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / Chromogranins; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / FKBP10 protein, human; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


100. Hasumura M, Imai T, Takizawa T, Ueda M, Onose J, Hirose M: Promotion of thyroid carcinogenesis by para-aminobenzoic acid in rats initiated with N-bis(2-hydroxypropyl)nitrosamine. Toxicol Sci; 2005 Jul;86(1):61-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1 week after DHPN initiation, rats in groups 2, 3, 4, and 6 were fed basal diet containing 0.25%, 0.5%, 1.0%, and 1.0% PABA, respectively, for 40 weeks.
  • Rats in groups 1 and 5 received basal diet alone throughout the experiment.
  • The final incidence of thyroid follicular cell adenomas and adenocarcinomas was significantly (p < 0.05 or 0.01) increased in groups 3 and 4 as compared to group 1.
  • In experiment 2, animals in group 1 were fed basal diet alone, while groups 2 and 3 were given 0.5% and 1.0% PABA in the diet, respectively, for 2 weeks.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. 4-AMINOBENZOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843508.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 0 / Thyroid Hormones; 53609-64-6 / diisopropanolnitrosamine; TL2TJE8QTX / 4-Aminobenzoic Acid
  •  go-up   go-down






Advertisement